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The age structure of the U.S. population is expected to change with the segment of the 
population aged over 65 years experiencing the largest increase in size. Given the expected 
change in the U.S. population, efforts aimed at screening and diagnosis, in addition to the 
prevention and treatment of diseases with a significant burden in older adults should be at the 
forefront of public health efforts.  Accordingly, in order to obtain an appreciation of the 
significance of cardiovascular diseases in older adults we initially performed a literature review 
of the burden and prevention of cardiovascular diseases, the leading cause of morbidity and 
mortality in older adults.  Subsequently, we focused our research efforts on cardiorespiratory 
fitness in older adults.  Cardiorespiratory fitness is a determinant of morbidity and mortality in 
middle-aged and older adults which can be measured objectively by either exercise testing or 
walk-based tests.  Few studies of community-dwelling older adults have characterized the 
relationship between fitness as assessed by exercise testing versus walk-based testing, with 
subclinical cardiovascular, or the prognostic significance of walk-based test performance.  We 
sought to characterize these relationships among community-dwelling adults participating in the 
Cardiovascular Health Study (CHS).  In an analysis of the  Arterial Calcification in the Elderly 
(ACE-CHS),  6 Minute Walk test (6 MWT) performance was a useful measure of treadmill test 
capability and performance.  A second analysis of ACE-CHS failed to identify subclinical 
cardiovascular disease as quantified by the coronary artery calcification score as a significant 
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determinant of exercise duration in exercise treadmill testing.  However, the coronary artery 
calcification score was associated with ischemia as detected by electrocardiographic changes 
during exercise testing.  Finally, in the full CHS cohort, the 6 MWT performance was 
independently associated with all-cause mortality, demonstrating a prognostic value for 
submaximal fitness assessment using the 6 MWT across a wide range of function present in 
community-dwelling older adults.  The public health relevance of these finding is the potential 
clinical utility of the 6 MWT, a quick, safe and inexpensive alternative to exercise treadmill 
testing, in the assessment of cardiorespiratory fitness and the prediction of mortality in 
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1.0  INTRODUCTION 
The age structure of the U.S. population is expected to change dramatically over the next 50 
years with a nearly two-fold increase in the proportion of population aged ≥65 by year 20501.   
While adults aged 65-84 years accounted for 10.9% of the total population in the year 2000, this 
proportion is estimated to increase to approximately 16% by year 2050.  As for individuals aged 
≥85 years, it is estimated this segment of the population will account for 5.0% of the total 
population in the year 2050, representing a greater than two-fold increase from that in the year 
20002.  In terms of absolute numbers, given the concurrent projected growth of the overall 
population size, the number of adults aged ≥85 years is estimated to increase from approximately 
4.3 million in the year 2000 to nearly 21 million by the year 20502.   The projected change in the 
U.S. age distribution is of public health significance in terms of burden from morbidity, 
mortality, and costs related to cardiovascular diseases.   
The age-related increase in cardiovascular disease morbidity and mortality can be 
appreciated by consideration of the population-based disease-specific incidence and prevalence 
of cardiovascular diseases, including the overall cardiovascular disease, coronary heart disease, 
peripheral arterial disease, heart failure, valvular heart disease.  Similarly, a review of measures 
of subclinical cardiovascular disease, such as age-associated changes in coronary artery 
calcification is insightful.  The importance of the relationship between physical activity and 
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fitness with age and also their association with morbidity and mortality will provide an important 
perspective of the public health impact of the aging U.S. population. 
1.1 EPIDEMIOLOGY 
In 2005 cardiovascular disease was the underlying cause in 864,480 out of approximately 2.5 
million deaths of which adults aged ≥65 years accounted for the largest absolute numbers (Figure 
1.1)2.  In terms of morbidity, an estimated 80 million U.S. adults have at least one type of 
cardiovascular disease (CVD) and nearly one-half of which are aged ≥60 years2.  In fact, there is 
marked increase in the incidence and prevalence of CVD with advancing age.  The prevalence of 
CVD, including hypertension, coronary heart disease (CHD), heart failure (HF), and stroke, 
increases from about 40% in men and women 40-59 years of age, to 70-75% in persons 60-79 
years of age, and to 79-86% among those aged 80 years or older (Figure 1.2)2.  Similarly, the 
incidence of CVD, including CHD, HF, and stroke or intracerebral hemorrhage, increases from 
4-10 per 1,000 person-years in adults aged 45-54 years to 65-75 per 1,000 person-years in adults 
aged 85-94 years (Figure 1.3)2. 
1.1.1 Cardiovascular Disease 
In the United States, cardiovascular diseases account for more deaths than any other major 
causes of death with coronary heart disease and stroke accounting for approximately two-thirds 
of CVD deaths while the remaining CVD deaths are due to heart failure (7%), high blood 
pressure (7%), diseases of the arteries (4%), and other (14%)2.   In 2005, approximately 80% of 
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the 864,000 CVD deaths occurred in adults aged ≥65 years and nearly 40% of the CVD deaths 
occurred in adults aged ≥85 years2.   In fact, the proportion of deaths due to CVD increases with 
advancing age.  For instance, the 2004 percent of CVD deaths in US adults aged ≥85 years was 
48% compared to 20% in those aged 35-44 years2.   Comparison of 65-74 with 75-84 year old 
age groups reveals a nearly two-fold difference in the death rate due to HF, CHD, and stroke2. 
Although CVD is often thought to affect men more commonly than women, beyond 
approximately 60 years of age the prevalence of CVD is higher among women than men.  In 
2005, more than 200,000 of the 454,613 CVD deaths occurred in women aged ≥85 years 
compared to approximately 100,000 out of 409,867 CVD deaths observed in men aged ≥85 
years2.    
1.1.2 Coronary Heart Disease 
Coronary heart disease (CHD) is the most common form of CVD and accounts for more than 
half of all CVD-specific mortality.   In 2005, CHD mortality accounted for a total of 445,687 
CVD deaths of which the proportion accounted for by individuals aged ≥65 years was nearly 
82%2.  In both men and women, there is a marked increase in the prevalence of CHD with age 
(Figure 1.4)2.  As for the incidence of CHD among older adults, the 10-year rate of MI increases 
with age among older adults aged ≥65 years regardless of race or gender (Figures 1.5 and 1.6)2.  
Even at the advanced age of 70 years, there still remains a 34.9% and 24.2% lifetime risk of a 
first coronary heart disease event in men and women, respectively3.  
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1.1.2.1 Myocardial infarction 
In addition to a poorer prognosis, Myocardial Infarction (MI) becomes more prevalent in old age 
as evident by a nearly seven-fold increase in MI prevalence comparing ages 35-44 to 65-74 
years4.  This pattern of age-related increase in MI prevalence extends into the oldest old age 
groups and by a greater magnitude in women.  For instance, the MI prevalence in CHS women 
increased from 9.7% in adults aged 65-69 years to nearly 18% in women aged ≥85 years 
representing an increase of nearly two-fold in magnitude5.  
Annually, there are nearly half a million adults aged ≥75 years diagnosed with an MI2.  
Relative to the younger age group 35-44 years, men and women aged 65-74 years have an 
approximately ten- and an approximately 6-fold increase in the incidence rate MI, respectively.  
This represents an increase from approximately 1.0 to nearly 10 per 1,000 person years in men. 
For CHS women, the incidence rate increased from 0.3-0.7 to 5.1-7.2 per 1,000 person-years 
when comparing age groups of 35-44 to 65-74 years6.  Data from CHS shows that the age-related 
increase in MI incidence continues into oldest age groups as evident by a two- and three-fold 
increase in the incidence rate of MI from the age of 65-69 to the oldest age groups (Figures 1.7 
and 1.8)6. 
As for the prognosis of an MI in older adults, it is associated with both a poor short- and 
long-term prognosis as reflected by a likelihood of recurrent MIs and mortality2, 7.   Adults aged 
≥75 years with history of MI have a nearly 1.5-2-fold increased likelihood of recurrent MI, 
stroke, and heart failure when compared with those aged 40-69 years2.  Likewise, in terms of 
mortality, individuals aged ≥75 years with a history of MI have a 1.5-fold increased 5-mortality 
when compared to adults aged 40-69 years2. 
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1.1.3 Heart Failure 
In 2005, heart failure (CHF), a disease of the predominantly older adults, was the underlying 
cause of approximately 59,000 deaths and mentioned on nearly 300,000 U.S. death certificates2, 
8.  The aging population combined with improved survival from comorbid conditions, such as 
coronary heart disease and hypertension, have led to an increase in both the prevalence and 
incidence of heart failure. While heart failure is relatively uncommon in adults aged 20-39 years 
with a prevalence of 0.1-0.2%, its prevalence increases to 5-10% in adults aged 60-79 years, and 
12-14% by age ≥80 years2.  Among community-dwelling older adults, the 18% prevalence of 
CHF in CHS men aged ≥85 years is higher than the 12% prevalence observed in men in the 
younger age group of 66-69 years.  Likewise in CHS women aged 66-69 years, the 6% 
prevalence of CHF is less than half of the 14% prevalence observed in women aged ≥85 years9.   
In addition to the high prevalence of CHF, older adults free of prevalent CHF continue to 
have an approximately 1 in 5 lifetime risk for incident CHF9.  For instance, men aged 80 years 
free of prevalent CHF have a 20.2% risk for developing CHF which is close to the 21.0% 
lifetime risk for 40 year old men.  However, unlike the case of younger adults, the risk in older 
individuals is much greater in the short term.  For instance, while the 5-year risk of CHF for an 
80 year old is around 8%, the risk for a 40 year old is much lower at approximately 0.2%.   
According to CHS data, the 10-year incidence rate of CHF in older adults 65 years and 
older increases up to six-fold across age strata6.  There is a three- and six-fold increase in the 
incidence rate of CHF by age 85 years and older in Caucasian men and women, respectively 
(Figure 1.9)6.  Similarly, in African American men and women, there is an approximately three-
fold increase in the incidence rate of CHF across age strata (Figure 1.10)6. In both Caucasian and 
African Americans, older men have a higher overall 10 year incidence rate of CHF than women 
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participating in the Cardiovascular Health Study.  While the incidence rate of CHF in adults aged 
≥65 years is higher in Caucasian men than in African Americans, the reverse is true for CHF 
incidence with respect to race in women (Figures 1.9 and 1.10)6.   
1.1.4 Stroke 
Stroke is the third leading cause of death and a leading cause of long-term disability in the U.S.  
While the prevalence of stroke is below 3% in adults aged 20-59 years, it increases to 
approximately 8% by age 60-79 years, and reaches 13-17% for adults aged ≥80 years2.   
The overall 10-year incidence rate for stroke in CHS men and women range from 13.7-
14.7 per 1,000 person-years6.   In the CHS cohort of older adults aged ≥65 years, the overall 10-
year incidence rate in African American women is higher than in Caucasian women. In contrast, 
the overall 10-year incidence of strokes is higher in older Caucasian men than in African 
American men6.   Similar to many other common CVD types, the incidence of stroke increases 
with age.  The stroke incidence rate increases two- to five-fold across advancing age groups 
(Figures 1.11 and 1.12)6.  
1.1.5 Peripheral Arterial Disease 
Peripheral arterial disease (PAD) is a significant predictor of cardiovascular and overall 
mortality.  In addition, PAD has been shown to be associated with limitations due to physical 
function inversely related to health-related quality of life10, 11.  Peripheral Arterial disease, as 
measured by an ankle brachial index (ABI) <0.9, was found to be present in 12.4% of 5,084 CHS 
participants12.   In a cohort of CHS participants free of prevalent CVD, there was nearly a three-
 7 
fold increase in the prevalence of men with ABI<0.9 with advancing age reaching a prevalence 
of approximately 30% in men aged ≥85 years12.   Similarly, in CHS women free of prevalent 
CVD, the prevalence of ABI<0.9 was nearly 40% in participants aged ≥85 years which is 
approximately eight-fold higher than the prevalence in women aged 65-69 years12. 
1.1.6 Valvular Heart Disease 
In 2005, diseases of the heart valves accounted for 93,000 hospital discharges and nearly 21,000 
deaths out of which approximately 13,000 were due to aortic valve disease2.  The prevalence of 
aortic stenosis (AS), defined as thickened leaflets with reduced systolic openings on two 
dimensional imaging and an increased anterograde velocity (≥2.5 m/s by continuous wave 
Doppler ultrasound), increases across advancing age groups among elderly participants of the 
Cardiovascular Health Study.   While the prevalence AS is 1.3% in adults aged 65-74 years, by 
age 75-84 years the prevalence increases nearly two-fold to 2.4%, and  the prevalence of AS 
reaches 4% among adults aged ≥85 years13. 
The Healthy Ageing Study reported on the prevalence of aortic valve abnormalities by 
severity of stenosis using ultrasound recordings of 552 participants14.  The age distribution 
ranged from 51 to 86 years consisting of a sample size of 197 participants aged 75-76 years, 155 
participants aged 80-81 years, and 124 participants aged 85-86 years.  By accounting for the 
possibility of a narrow left ventricular outflow tract found in the elderly, these investigators 
defined aortic stenosis based on a calculated velocity ratio≤0.35 in combination with a calculated 
aortic valve area (AVA) ≤1.2 cm2 for moderate and AVA ≤0.8 cm2 for critical aortic valve 
stenosis.  Based on this definition of AS, the overall prevalence of at least moderate and critical 
aortic stenosis in adults aged 75-86 years were 4.8% and 2.9%, respectively.  There is an 
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increase in the prevalence of both of these categories of AS with age.  The prevalence of at least 
moderate severity aortic stenosis increased from 2.5% for adults aged 75-76 years, to 3.9% in 80-
81 years old, and 8.1% by ages 85-86 years.  The prevalence rates for critical aortic stenosis for 
these same age groups categories was reported to be 0.5%, 2.6%, and 5.6%, respectively.    
1.1.6.1 Valvular Regurgitation  
The prevalence of valvular regurgitation, including mitral, tricuspid, and of aortic valves, was 
determined for participants aged 26 to 83 years in the Framingham Heart Study15.   The 
prevalence of valvular regurgitation abnormalities, assessed using color Doppler 
echocardiography, increases with age in both genders. In men, the prevalence of at least mild 
severity mitral regurgitation increases nearly four-fold from 8.9% in adults aged 26-39 years to 
39.3% in adults aged 70 – 83 years.  The prevalence of at least mild tricuspid regurgitation in 
men increases more than two-fold from 13.0% in adults aged 26-39 years to 27.3% in adults 
aged 70-83 years.  Similarly, the prevalence of aortic valve regurgitation in men increases from 
0% in 26-39 year olds to 14.4% in men aged 70-83 years. The prevalence of at least mild degree 
of mitral, tricuspid, and aortic valve regurgitation in women aged 26-39 years are 9.7%, 14.4%, 
and 0%, respectively.  By ages 70-83 years, these prevalence rates increase to 23.6%, 29.5%, and 
16.9%, respectively.  The age-related increase in the prevalence of various types of valvular 
heart disease has been confirmed by a pooled analysis of echocardiography data from 11,911 
participants of the three epidemiologic studies of Coronary Artery Risk Development in Young 
Adults (CARDIA), Atherosclerosis Risk in Communities (ARIC), and the Cardiovascular Health 
Study16.   
In contrast to the other forms of valvular heart diseases, the prevalence of mitral valve 
prolapse (MVP) has not been observed to vary significantly with age17.   Based on data from 
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3491 Framingham Heart Study participants with mean age 54.7 (Range: 26 to 84 years), the 
overall prevalence of MVP is 2.4%.  The prevalence of MVP did not vary significantly across 
advancing decades of age from the age of 30 to 80 years. 
1.1.7 Atrial Fibrillation and Other Electrocardiogram Abnormalities 
1.1.7.1 Atrial Fibrillation 
While the prevalence of atrial fibrillation (AF) was estimated to be 2.2 million in 2005, it is 
projected that by 2050 the number of individuals with AF will exceed 10 million2, 18.   In 
participants of CHS, the overall prevalence of AF in men and women was observed to be 6.2% 
and 4.8%, respectively19.  The prevalence of AF varied by cardiovascular disease status, such 
that the prevalence was 8.7% in men with clinical CVD, 4.5% with subclinical CVD, and 1.1% 
in men without known cardiovascular disease19.  The prevalence of AF in women with clinical 
was 9.4%, 4.7% with subclinical CVD, and 2.7% in women without cardiovascular disease19.  
Regardless of CVD status, the prevalence of AF increased with age such that the prevalence 
increased from 2.8% in women aged 65-69 years to 6.7% in women aged ≥80 years19.  Similarly 
in men aged 80 years and older the prevalence of atrial fibrillation of 8.0% was higher than the 
5.9% observed in men aged 65-69 years19.   
The lifetime risk for atrial fibrillation in adults without known CHF or MI remains 
approximately 15% in adults aged 40 years as well as in individuals aged 80 years20.  The overall 
incidence rates of atrial fibrillation in elderly participants of the Cardiovascular Health Study 
were 26.4 and 14.1 per 1,000 person-years, for men and women respectively21.   There is an age 
associated increase in the incidence of AF in both genders such that the incidence of 12.3 person 
years in men aged 65-69 years increases to 58.7 per 1,000 person-years by the age ≥80 years.  
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Similarly, the incidence rate of atrial fibrillation in women increases from 10.9 per 1,000 person-
years in women aged 65-69 years to 25.1 per 1,000 person-years in women aged ≥80 years21. 
1.1.7.2 Abnormalities of the Electrocardiogram  
Resting Electrocardiogram (ECG) abnormalities are quite common in older adults.  Evaluation of 
the ECGs from 5,150 CHS participants revealed an overall prevalence of any ECG abnormality 
to be 28.7%22.  The prevalence rate for the presence of any ECG abnormality increases across 
age groups from 16.0% in men aged 65-69 years, to 27.5% by age 75-79 years, and 45.9% by 
age ≥85 years22.  Similarly in women the prevalence of ECG abnormalities increases across age 
groups from 10.5% in age 65-69 years, to 20.2% by age 75-79 years, and 31.6% by age ≥85 
years22.  The observed prevalence, from most common to least, of the different types of ECG 
abnormalities, are 8.7% for ventricular conduction defects, 5.3% for first-degree atrioventricular 
block, 3.2% for atrial fibrillation, 6.3% for isolated major ST-T wave abnormalities, 4.2% for left 
ventricular hypertrophy, and 5.2% for major Q/QS waves22.  The most common among the 
ventricular conduction defects was a Right Bundle Branch Block with a prevalence of 4.3%, 
followed by intraventricular block of indeterminate type at 2.7%, followed by a prevalence of 
1.7% for Left Bundle Branch Blocks22.    
Twenty-four hour ambulatory electrocardiography has been evaluated in 1,372 CHS 
participants and revealed that the presence of minor supraventricular arrhythmias or any 
supraventricular ectopic beats is extremely common in the elderly and observed in approximately 
97% of older adults23.   Only 2.8% of elderly CHS participants were free of supraventricular 
arrhythmias and only 18% were without any ventricular ectopic activity23.  Frequent ectopic 
beats, defined as ≥15 beats per hour, were recorded in nearly half of men and women and were 
more commonly of supraventricular origin.  Although less common, ventricular ectopic beats 
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were observed in 57.1% and 55.5% of men and women, respectively23.  The prevalence rates for 
ventricular tachycardia, defined as ≥3 complexes, were 13% and 4.3% in men and women, 
respectively23.  Supraventricular tachycardia, defined as ≥3 complexes, was seen in 47.7% and 
49.9% of men and women, respectively23.  There is an age-related increase in the prevalence of 
supraventricular arrhythmias and by age ≥80 years is observed in more than three-quarters of 
subjects23.   However, serious arrhythmias including sustained ventricular tachycardia (≥15 
complexes) and complete atrioventicular blocks were rarely detected (≤0.5%) in community-
dwelling older adult participants of CHS23.   
1.1.8 Subclinical Cardiovascular Disease 
The presence of various types of subclinical CVD can be measured by noninvasive methods such 
as the ankle-arm blood pressure, carotid ultrasound of carotid arteries, and an electrocardiogram, 
Magnetic Resonance Imaging of the brain, and Computed Tomography scanning of the heart and 
coronary arteries.  The prevalence of such subclinical CVD increases with age24.  For example, 
the prevalence of brain white matter changes and coronary artery calcium score increase 
progressively with age in both men and women25-27.  In the case of subclinical peripheral arterial 
disease in CHS participants, defined as AAI<0.9, the prevalence increased approximately three 
and 8-fold from the age 65-69 years to those aged ≥85 years in women and men, respectively.  In 
addition to being of prognostic significance, the presence of subclinical disease impacts physical 
and cognition function.  In CHS, for example, compared to people 65 years of age or older with a 
normal ABI (i.e., ≥ 0.9), those with an ABI < 0.8 had a 3.5-fold increased risk of frailty28. 
Alternatively viewed, the presence of subclinical CVD among participants in CHS was 
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associated with a loss of approximately 6.5 years of “successful” life (i.e. with good health and 
function) in women and 5.6 years in men29. 
1.1.8.1 Calcification of the Heart Structures 
Calcification of the cardiac structures, a marker of increased CVD risk, is commonly detected in 
older adults30.  For example, a necropsy study of 490 cases aged ≥80 years found that calcified 
deposits were present in 91%31.  The calcification of the heart structures varies in location, 
including the coronary arteries, aortic valve cusps, mitral valve annulus, and the left ventricular 
papillary muscles, and is of prognostic significance32.   
Calcification of the aortic valve is a common finding in advanced age13, 14.  In adults, it is 
present in 53% of the adults over the age of 55 years while there was a decrease in the proportion 
free of any valvular calcification with advancing age14.   While 72% of persons aged 55-71 years 
were found to be without aortic valve calcification in persons aged 55-71 years, this proportion 
decreased to only 25% of individuals aged 85-86 years.  The prevalence of slight aortic valve 
calcification increases nearly three-fold from 21% in 55-71 year olds to 56% in adults aged 85-
86 years.  Similarly, the prevalence of severe aortic valve calcification increases from 7% in 55-
71 year olds to 19% in persons aged 85-86 years. 
In addition to valvular calcification, sclerosis of the valve has been shown to be present 
and carry prognostic importance.  Aortic valve sclerosis, defined as increased echogenicity and 
leaflet thickness without restriction of leaflet motion, is associated with an increase of 
approximately 50% in the risk of CVD death and incident MI33.   Aortic valve sclerosis was 
reported to have an overall prevalence of 26% in CHS participants13.   The sclerosis of the aortic 
valve increases in prevalence from 20% in 65-74 year olds, to 35% in 75-84 year olds, and 
reaches 48% for adults aged ≥85 years.   
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Mitral Annular Calcification (MAC), a degenerative calcification of the mitral valve 
support ring, has been shown to be independently associated with 1.5- to two-fold increase in 
risk of incident stroke and other CVD events, CVD- and all-cause mortality34,35.   The 
relationship between mitral annular calcification with advancing age has been observed in a 
number of clinical and autopsy studies.  Similar age-related increases in the presence of MAC 
have been found in epidemiological studies, including the Cardiovascular Health Study and the 
Framingham Heart Study (FHS), regardless of mode of MAC detection. 
Mitral annular calcification (MAC), defined as an intense echocardiograph-producing 
structure located at the junctions of the atrioventricular groove and posterior mitral leaflet on the 
parasternal long-axis, apical 4-chamber, or parasternal short-axis view, was assessed using two-
dimensional echocardiography in CHS participants and found to have an overall prevalence of 
42% 32.     The prevalence of MAC increases nearly two-fold from approximately 35% in 65-74 
year olds to nearly 60% by age ≥85 years.   
 In the FHS, mitral annular calcification was defined as the presence of an echo-dense 
band located immediately behind the posterior mitral leaflet and was assessed using M-mode 
echocardiography35.   The overall prevalence of MAC in 5,694 FHS participants was 2.8%.  The 
prevalence of MAC, in both men and women, was found to increase with age.  In contrast to 
individuals younger than 59 years of age, in whom the prevalence was less than 1%, males and 
females in the oldest age groups of ≥80 years increased to 22.4% for females and 6.0% in males.  
Despite differences in echocardiography detection, both epidemiologic studies detected an 
increase in the prevalence of MAC with advancing age. 
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1.1.8.2 Calcification of the Coronary Arteries 
Coronary arteries may also exhibit calcification and the amount of coronary artery calcification 
correlates with the atherosclerotic plaque burden36.  The amount of CAC can be quantified by 
non-invasive methods, including electron-beam computed tomography (EBT) and multi-
detector computed tomography (MDCT), and commonly reported using the agatston scoring 
method37.  As previously mentioned, CAC is useful in CVD risk prediction and adds to models 
incorporating traditional CVD risk factors and therefore some national guidelines have 
incorporated them into their risk stratification models38.  Moreover, the prognostic utility of CAC 
in prediction of coronary events has been demonstrated in various races39. 
There is a strong association between CAC and age with a wide range of CAC scores in the 
oldest old26 .  Older adults with CAC are more likely to have prevalent subclinical and clinical 
CVD40. Given its association with prevalent CVD, CAC remains discriminatory for future CVD 
in older adults.  In addition to the relationship with coronary events, CAC in older adults has 
been associated with reduced physical function41.  
1.2 ASSESSMENT OF CARDIOVASCULAR RISK  
The method endorsed for the CVD risk stratification and subsequent management of all persons 
is based upon a global risk assessment42,43.  The Framingham Heart Study’s Global Risk Score 
stratifies individuals into one of three categories (low, intermediate, high) based upon a 10-year 
estimate of CHD risk and serves as a risk stratification tool42.  While a 10-year risk estimate of 
less than 10% represents a low risk, estimates of 10% to 20% and ≥20% represent an 
intermediate and high risk, respectively.  When this method is used for cardiovascular risk 
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stratification in older adults, age is weighted so heavily that in many cases, treatment decisions 
could be made on the basis of age alone. In Cardiovascular Health Study, men over 65 and 
women over 75 years of age had an absolute rate of CHD morbidity and mortality exceeding 2% 
per year or 20% over 10 years, thus would be candidates for preventive intervention of the same 
level of aggressiveness as other high risk groups6.   
 The measurement of subclinical CVD, in addition to age, has also been proposed as a 
method of risk stratification44.   Several methods, including the coronary artery calcium score 
provide additional discrimination even taking into account traditional risk factors45.  In fact, 
coronary artery calcium has been shown to do better than age itself as a predictor of CHD risk 46.   
Conventional cardiovascular risk factors, including hypertension, hyperlipidemia, 
smoking, physical inactivity, diabetes mellitus are highly prevalent in individuals with 
cardiovascular disease47 .  Except for smoking, the prevalence of every major cardiovascular risk 
factors increase with age48. Additionally, epidemiologic studies have revealed a number of the 
primary risk factors for an incident myocardial infarction, such as diabetes, hypertension, 
dyslipidemia, and smoking, remain of  prognostic significance for not only the initial but also 
recurrent CVD, in addition to mortality49-53.   For instance, the presence of diabetes remains a 
significant predictor poor prognosis after a myocardial infarction52.  Based on data from 1,635 
participants (aged 45-70 years)  of The Stockholm Heart Epidemiology Program (SHEEP), the 
presence of diabetes was associated with an adjusted hazard of 1.6 (95% CI: 1.0-2.4) in men and 
2.5 (95% CI: 0.9-6.9) during a median follow-up of 7.2 years post-MI 54.  As for the association 
between dyslipidemia and recurrent CVD events, several clinical trials have revealed that lipid 
lowering therapy with statins results a reduced risk for recurrent events55-57.  Of note, the 
findings from studies reporting on the impact of smoking status on risk of recurrent events have 
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been mixed.  Despite mix findings, it has been found that there is an elevated risk of recurrent 
coronary events in active smokers.  Based on Health Maintenance Organization data from 2,619 
survivors of myocardial infarction, the risk of recurrent coronary events was significant in active 
smokers (Hazard Ratio: 1.51, 95% CI: 1.10-2.07)53.  In addition, among smokers who quit 
smoking after initial MI there is a decrease in risk of recurrent events with time such that by 3 
years after cessation the risk approaches that of non-smokers.  
Other factors including increased adiposity, a low socioeconomic status, psychosocial 
factors (i.e., job strain), an elevated plasminogen activator inhibitor 1, and elevated inflammatory 
markers, such as C-reactive protein, remain as significant risk factors for recurrent CVD 
events58-62.   
Conventional risk factors are associated with CVD and remain important for risk 
prediction in old age.  Moreover, given that the magnitude of the impact from preventative 
measures depend on the absolute baseline risk, the higher baseline CVD risk in older adults 
translates into a greater absolute CVD risk reduction.  However, several factors make the 
interpretation of the associations between risk factors and CVD in the older adults challenging.  
The relative risks for some cardiovascular risk factors decrease in magnitude with an increase in 
age while their absolute effects become greater at old age63, 64. This has lead to misconceptions 
about the importance of these risk factors in old age.   Relative risk represents a ratio of risk for 
developing the outcome, such as CVD, in individuals having a high level of a risk factor in 
comparison to those with low levels.  One major reason for this relative reduction in risk is that 
the comparison group includes many individuals whose risk factors, for example cholesterol, 
have declined secondary to comorbid illness, therefore reducing the apparent relative differences. 
The absolute risk of CVD associated with risk factors continue to increase with age and most 
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trials of risk factor reduction show marked decreases in absolute risk, with a much smaller 
number needed to treat.  
1.3 PREVENTION OF CARDIOVASCULAR DISEASE 
The approach to CVD prevention is in large part similar across all ages.  The combination of 
pharmacologic therapy, including anti-platelet, anti-hypertensive and lipid lowering medications, 
along with therapeutic lifestyle changes (TLC) including physical activity may be appropriate 
based on individual risk.  Evidence from clinical trials supports the role of TLC in achieving a 
favorable risk factor profile.  The favorable impact of physical activity of the traditional risk 
factors are discussed later in this review.   
1.3.1 Anti-Hypertensive Therapy in Older Adults 
Hypertension is highly prevalent in the U.S. with an estimated 42.7 million adults being 
identified as hypertensive according to data from the Third National Health and Nutritional 
Examination Survey (NHANES III)65.  Hypertension is also highly prevalent in old age, present 
in nearly two-thirds of individual aged ≥ 65 years.  According to NHANES III data, the 
prevalence of hypertension increases from 3.4-8.6% in individuals aged 20-34 years, to 42.9-
44.2% in persons aged 55-64 years, and increases to 64.2-77.3% in individuals aged ≥75 years66.  
In addition to being commonly present in older adults, hypertension in the elderly remains a risk 
factor for coronary events, strokes, and peripheral arterial disease increasing the relative risk of 
their occurrence nearly 1.5-2.5 fold67-70.   
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Several major clinical trials have been conducted specifically in older adults and have 
demonstrated that blood pressure control is critical to prevention of heart disease, stroke, and 
mortality in older adults (TABLE 1.1)56, 71-76.  Prior to availability of the results from the 
Hypertension in the Very Elderly Trial (HYVET), trials of antihypertensive therapy had 
established the beneficial effects of blood pressure lowering on CVD outcomes, including 
strokes and other vascular events, in adults up to approximately 80 years of age.   These major 
randomized trials in older adults have clarified the role of antihypertensive therapy for 
prevention of CVD events in older adults (ages up to approximately 80 years) with either 
isolated systolic hypertension56, 76  or an elevation of both systolic and diastolic blood pressure71, 
74.  However, given the existing evidence for an inverse relationship between blood pressure and 
the risk of death among individuals 80 years of age and older it had remained unclear whether 
the benefits of anti-hypertensive therapy could be extrapolated to adults aged ≥ 80 years77-79.  
Two studies, a subgroup meta-analysis of randomized control trials of anti-hypertensive drugs in 
the elderly and a randomized placebo controlled trial, investigated the role of anti-hypertensive 
therapy in the subpopulation of elderly aged ≥80 years73, 75.  The subgroup meta-analysis of a 
total of 1,670 adults aged ≥80 years suggested that anti-hypertensive therapy in this 
subpopulation results in a 34% reduction in strokes, 22% reduction CVD events, and 39% 
reduction in heart failure.  However, relationship between antihypertensive therapy and mortality 
in persons aged ≥80 years remained unanswered until the results of HYVET became available.  
The HYVET trial, which was a randomized placebo controlled trial of 3,845 adults aged ≥80 
years (mean age, 83.6 years), used a diuretic-based anti-hypertensive treatment regimen to 
achieve the target blood pressure (BP) of 150/80 mm Hg73.  After a median follow-up duration of 
1.8 years, anti-hypertensive therapy resulted in a significant 30% reduction in strokes and 64% 
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reduction in heart failure.  Additionally, there was a significant 21% reduction in all-cause 
mortality in the treatment arm relative to placebo.  In summary, treatment of hypertension in the 
elderly is beneficial in preventing strokes, heart failure, and mortality.   
Questions do remain about what should be used as the appropriate target blood pressure 
(BP) for older adults. The target BP used in existing trials regarding BP lowering in hypertensive 
elderly (ie, 150/80 mm Hg in HYVET) are different from published guidelines80.  Current 
approaches should take this into account when translating these guidelines to older adults. While 
keeping to the published BP targets, the clinicians should be aware of the major benefit achieved 
in studies of older adults that have lower blood pressure by 25 mmHg or to less that 150/90 mm 
Hg. 
Additional outcomes where the data regarding the use of anti-hypertensive therapy are 
not yet definitive relates to the effects on cognitive decline and dementia.   Anti-hypertensive 
therapy may maintain cognitive functioning by reducing the progression of cognitive impairment 
and the reduction of incident dementia81, 82.  The vascular dementia project, which was part of 
the Syst-Eur trial, aimed at comparing antihypertensive treatment with placebo in 2,418 adults 
aged ≥60 years (mean age, 69.9 years) in terms of their association with the risk of incident 
dementia.  In this study, an incident dementia was initially detected based on a Mini-Mental 
State Exam (MMSE) and confirmed in participants with an MMSE score of 23 or less using the 
criteria set by the Diagnostic and Statistical Manual of Mental Disorders, revised (DSM-III-R).  
Following a median duration of 2.0 years, anti-hypertensive therapy with Nitrendipine, a calcium 
channel blocker, alone or in combination with an Angiotensin Converting Enzyme Inhibitor 
(ACEI) or a Thiazide diuretic resulted in a 50% relative reduction in incident dementia.  
Although a report by SHEP investigators failed to find a significant association between diuretic-
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based anti-hypertensive therapy with Chlortalidone, follow-up analysis raised the possibility this 
finding may have been biased by differential dropout81, 83.  
Another topic of importance in approaching CVD risk reduction in older adults is the 
choice of anti-hypertensive medication.  The Antihypertensive and Lipid Lowering Treatment to 
Prevent Heart Attack Trial (ALLHAT), which provided guidance on this issue, was a 
randomized active-controlled trial of 33,357 hypertensive adults with 1 additional CVD risk 
factor comparing four classes of antihypertensive agents84.  The study population included 
24,330 individuals aged ≥55 years.  The primary outcome of ALLHAT was a combined fatal 
CHD or nonfatal MI.  The secondary outcomes were all-cause mortality, stroke, combined CHD 
(primary outcome, coronary revascularization, or angina with hospitalization), and combined 
CVD (CHD, stroke, treated angina without hospitalization, heart failure, and peripheral arterial 
disease).  The ALLHAT investigators concluded that treatment with a Thiazide diuretic is 
preferred as the initial-step in therapy of most patients with hypertension85. This is in support of 
the Joint National Committee on prevention, detection, evaluation, and treatment of high blood 
pressure (JNC 7) recommendations for antihypertensive therapy in the general population of 
hypertensive persons, including older adults80.  
1.3.2 Lipid Lowering Therapy with Statins in Older Adults 
Similar to other preventive measure, the intensity of lipid lowering therapy is adjusted according 
to an individual’s absolute CVD risk. The recommendation by the Adult Treatment Panel III 
(ATP III) serves as a useful guide in achieving this task43, 86.  According to the guideline, those at 
high risk are individuals with known coronary heart disease or in whom the 10-year risk 
associated with their risk factors is estimated to be 20% or greater.  Also, persons with known 
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diabetes, metabolic syndrome, or an acute coronary syndrome, in addition to individuals with an 
established CVD are considered, are to be considered at very high risk.  While all persons in the 
high risk categories should have an LDL-C goal of <100 mg/dL, the target of an LDL-C <70 
mg/dL should be considered for adults at very high risk.  In the case of older adults, the evidence 
supports the use of Statin therapy in high risk older persons with or without an established CVD. 
Several studies of lipid lowering agents, the 3-hydroxy-3-mehtylglutaryl coenzyme A 
reductase inhibitors (Statins) in particular, have been conducted specifically in older adults or 
have included adequate number of older adults to support that effective and safely of lipid 
lowering with Statins to at least age 80.  The Statins have been shown to be effective in the 
reduction of Low Density Lipoprotein cholesterol (LDL-C) levels, CVD morbidity, and both 
CVD-specific and all-cause mortality.  These findings have been replicated in both studies with 
the goal of primary and secondary prevention of CVD.  Moreover, the beneficial effects on 
clinical outcomes have been shown to be independent of baseline cholesterol levels. 
Randomized trials have shown statins use to be efficacious for the primary prevention of 
CVD in high risk middle-aged adults and younger elderly (TABLE 1.2)87-91.  Additionally, a 
recent meta-analysis evaluating the role of statins in the primary prevention of CVD revealed 
that statin use resulted in significant reductions in major cardiovascular events, myocardial 
infarctions, all-cause mortality, and CVD mortality supporting the beneficial role of statins in 
primary prevention of CVD92.  
Secondary prevention trials of statins have revealed that statins are efficacious for adults 
of wide age range and across a broad range of baseline cholesterol values.  Several of these 
secondary prevention studies utilizing statins as the lipid lowering agent are displayed in TABLE 
1.355-57.  These randomized placebo controlled trials of statins in adults with established coronary 
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heart disease (CHD) have shown statins to be useful in reducing new events, including nonfatal 
MI, coronary revascularization, strokes, CHD-related mortality, and all-cause mortality.  Similar 
to findings of the CARE and LIPID trials with participants whose cholesterol levels were 
considered to be of average levels, the 4S trial revealed a beneficial effect of statins in secondary 
prevention by reducing incident events and mortality in both the young (aged <60) and older 
(aged≥60) participants with elevated cholesterol and prevalent CHD. 
Furthermore, based on the available data statins appear to have a favorable safety profile.  
Despite a concern for the association of statin use with increased cancer, meta-analyses of major 
statin trials have failed to replicate similar associations90, 93, 94.  Evidence from existing trials has 
found the side effects related to statin use to be infrequent95.  Moreover, there is no evidence to 
date to the fact that the statin safety profile would differ in the oldest old age group(ie, ages 80 
years and older). 
1.3.3 Aspirin Therapy in Older Adults 
Aspirin, a cyclooxygenase inhibitor which leads to the blockade of platelet thromboxane A2 
formation, is an effective primary and secondary prevention measure in high risk populations.  
However, the incorporation of aspirin therapy requires consideration for the associated increased 
risk of hemorrhage, including major gastrointestinal bleeding.  Based on a recent study, the 
estimated incidence rate ( per 1,000 person-years) of aspirin associated upper gastrointestinal 
tract complications among men and women without any prior risk factors or use of NSAIDS 
increases from 4.8 and 2.4 among adults aged 60-69 years to 12.0 and 6.0 in adults aged ≥ 80 
years96.  The rates of gastrointestinal harm associated with aspirin use are approximately two-
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fold greater than non-aspirin user and one-fourth the  rate associated with the combined use of 
aspirin with NSAIDS.  
          Prior guidelines recommended the use of aspirin for the primary prevention of CHD in 
both males and females considered to be at high risk97,98.  Based on the evidence from more 
recent studies, including the results the Women’s Health Study99, the U.S. Preventive Services 
Task Force (USPTF) has published their new recommendations100.   In the publication, the 
USPTF encourages aspirin use for the reduction of myocardial infarctions in men aged 45-79 
years and ischemic strokes in women aged 55-79 years when the potential benefit outweighs the 
harm of an increase in gastrointestinal hemorrhage.  The Task Force report provides estimates 
for the benefits associated with aspirin use, the number of MI’s in men and the number of strokes 
in women, utilizing the results of a recent meta-analysis of aspirin use for primary prevention 
which revealed that aspirin use was associated with a 32% relative reduction in MI and a 17% 
relative reduction in ischemic strokes101.  Similarly, the estimates of gastrointestinal harm were 
based on rates of gastrointestinal bleeding in non-NSAID taking persons who did not have upper 
GI pain or a history of GI ulcer96.  The 10-year CHD risk threshold at which the benefits of 
aspirin use for the prevention of MI in men outweighs the potential harm increases from 4% in 
men aged 45-49 years to 12% in men aged 70-79 years old.  Similarly in women, the 10-year 
CHD risk threshold at which the benefits of aspirin use for stroke prevention outweighs the 
potential harm increases from 3% in women aged 55-59 years to 11% in women aged 70-79 
years old.  However, more evidence is needed regarding the both the risks and the benefits of 
aspirin use in CVD prevention for older adults, especially the oldest old age group (ages 80 years 
and older). 
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1.3.4 Physical Activity and Fitness  
The Center for Disease Control/American College of Sports Medicine (CDC/ACSM) physical 
activity guidelines recommend a minimum of 30 minutes of moderate intensity physical activity 
on 5 or more days per week or vigorous activity of at least 20 minutes duration on 3 more days 
per week102.  In older adults, a daily walk of at least 20 to 30 minutes which is considered a 
moderate intensity activity would likely achieve a level of fitness resulting in significant 
reduction in mortality risk103. However, only 39% of U.S. adults aged 65 years and older meet 
the CDC/ACSM.  Given the projected growth of the segment of the U.S. population aged 65 
years and older in the future decades, prevention efforts promoting regular physical activity 
would lead to a substantial reduction in morbidity and mortality 42.   
1.3.4.1 Prognostic significance of Physical Activity and Fitness 
Physical activity or fitness has a favorable impact on the risk of mortality. For instance, the 
benefit anticipated if a physically unfit man or woman would become fit would be a change of 
36.7% and 48.4% reduction in his or her risk of dying104.  In order to place into perspective, a 
man or woman with high serum cholesterol (≥ 6.2 mmol/L) would reduce their risk by 39.3% 
and 40.5% if he or her lowered it, respectively104.  In comparison, a man or woman with a high 
systolic blood pressure (≥ 140 mm Hg) would reduce their risk by 26.5% and 55.1% if he or her 
lowered it, respectively104.  In terms of the impact at the population level, the death rates would 
be a 9.0% lower in men and 15.3% lower in women if an unfit individual becomes fit104. 
 The favorable effect of physical activity level in reducing the risk of mortality due to 
premature CVD, CHD, and all-cause mortality in middle-aged adults has been observed by a 
number of observational studies105-108.  As in middle-aged adults, the inverse association between 
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physical activity and all-cause mortality has been shown in several studies of older adults109-115.  
Despite the number of studies on the inverse association between physical activity and CHD-
specific mortality in middle-aged adults, the literature on this relationship in older aged adults 
have been equivocal.  Table 1.4 displays the findings of several studies reporting on the 
relationship between physical activity in older adults with all-cause and CHD-specific mortality.  
Similarly, the summary of the findings of studies of the relationship between fitness in older 
adults with all-cause mortality is shown in Table 1.5. 
               The effect of physical activity has also been observed for leisure-time physical 
activity (LTPA)116.  Regular LTPA is associated with a lower risk for all-cause and 
cardiovascular disease morbidity and mortality in high risk middle-age adults.  A higher level of 
LTPA has been shown to be associated with reduced incident of coronary heart disease (CHD) 
and mortality117,118.  The Multiple Risk Factor Intervention Trial(MRFIT) reported on the 
association between LTPA with the first coronary heart disease event.  In the MRFIT study of 
12,138 middle-aged men (mean age 46 years) over a mean 7 years of follow-up revealed a 
statistically significant 36% relative risk reduction for coronary heart disease death and sudden 
death endpoint and a 27% risk reduction for all-cause mortality in moderately active individuals 
relative to light active group.  In addition, there was a favorable trend for the endpoint of 
nonfatal myocardial infarction when comparing the heavy versus the light physical active 
individuals.  Regarding the association of LTPA with reinfarction, among survivors of a first MI 
in the Corpus Christi Heart Project  (mean age of 60.2 years) those individuals who increased 
their LTPA had a higher reinfarction rate (17 per 1000 years) as compared to sedentary 
individual whose LTPA remained unchanged119.   
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1.3.4.2 Relationship of Fitness with Age 
Cardiorespiratory fitness or capacity declines with increasing age120, 121. The estimated decline 
with increasing in age ranges from 5.5% in trained master athletes to 12% decline in peak 
oxygen consumption per 10 year in sedentary adult men120.  While the rate is attenuated after 
accounting for muscle mass, this age-related decline in cardiorespiratory fitness is persists in 
both men and women122, 123.  In addition to age and gender, several other factors are have been 
associated with cardiorespiratory fitness including the duration, intensity, frequency, and type of 
physical activity, cardiovascular risk factors, clinical and subclinical disease, medications, and 
genetic factors124.  It has been estimated that genetic factors account from 25% to 40% of 
cardiorespiratory fitness125. 
1.3.4.3 Effects of Physical Activity on Cardiovascular Risk Factors 
The favorable effect of physical activity on CVD risk reduction is likely mediated via a 
combined favorable effect on traditional cardiovascular risk factors, non-traditional factors, and 
other unknown factors125.  Most physically active individual will have a change in the order of 
magnitude between 2% to 5% in their traditional cardiovascular risk factors, including 5% 
decrease in lipids126, 3 to 5 mm Hg lowering of blood pressure127, and a 1% lowering of 
HgbA1c128.  Additionally, regular physical activity result is reductions in  inflammatory 
markers128, including C-Reactive Protein129, 130.   
1.3.4.4 Assessment of Physical Fitness 
Cardiorespiratory or physical fitness is condition which is measured more objectively than the 
behavior of physical activity.  Physical activity is a behavior which is modifiable and that serves 
as a determinant of physical fitness104.  While fitness may serve as a marker of physical activity 
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level, the objective measurement of fitness is more precise than the self-reported physical 
activity typically captured via questionnaires131. While studies have between consistent with 
respect to the direction of association between fitness or activity and health outcomes, the 
objective measurement of fitness likely accounts for the greater strength of association between 
fitness and outcomes. 
              Fitness can either be measured by an exercise treadmill or cycle ergometer testing or 
walk-based tests.  The oxygen uptake (VO2), either peak or maximal, is a product of the cardiac 
output and arteriovenous oxygen difference is obtained from exercise testing. The oxygen uptake 
can also be reported in metabolic equivalents (METs), where one MET is equivalent to oxygen 
uptake of 3.5 mL/ kg per min.  The MET represents a ratio of the metabolic rate during exercise 
to the resting metabolic rate.  The oxygen uptake can either be directly measured or can also be 
estimated via established normograms with the direct measurement representing the gold 
standard132.   Several factors contribute to the discrepancy seen between directly measured versus 
estimated oxygen uptake including the level of familiarity with the treadmill protocol, use of 
handrail support, submaximal versus maximal testing, and population differences124. 
             Oxygen uptake is conventionally obtained according to either a maximal or sub-
maximal treadmill-based protocols or cycle ergometry exercise testing.   Treadmill-based and 
walk-based testing represent alternate methods for the assessment of functional exercise 
capacity124.  While the treadmill exercise test has been the most commonly applied method for 
the assessment of exercise capacity, older adults encounter greater limitations in their ability to 
execute a treadmill based exercise test133.  Moreover, the submaximal performance during a 
walking test in older adults may be a better reflection of daily activities and a more practical 
method of assessment than treadmill-based protocols134-136. 
 28 
Six Minute Walk Test 
The 6 MWT was introduced after 1976 with the use of the 12-minute corridor walking test137.  
The 6 MWT is a simple, safe, and easily administered test which has been studied in various 
disease specific populations, such as those with pulmonary disease, heart failure, pacemakers, 
peripheral arterial disease, and organ transplant candidates138-144.  In older adult populations the 6 
MWT is a reliable and valid measure of functional capacity145. The distance walked during six 
minutes has been shown to be an independent predictor of morbidity and mortality in various 
disease-specific populations as displayed in Table 1.6.    
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1.4 TABLES FOR INTRODUCTION 
Table 1.1 Studies of Anti-Hypertensive Therapy in Older Adults 
Study Population Treatment Follow-up Summary  
SHEP72 
n=4,736;                
Age: 72yr, 
mean                   
Diuretic (Chlorthalidone)             
or                                          
Placebo 
Mean:4.5yr 
A Significant 36% 
reduction in stroke, 54% in 
left ventricular failure, and 
a 33% reduction in 
myocardial infarction. No 
significant reduction in 
CVD-related or all-cause 
mortality. 
MRC71 
n=4,396;        
Age:70yr, 
mean                               
Diuretic (Chlorothiazide 
or Amiloride) or β-
blocker (Atenolol) 
or                            
Placebo 
Mean:5.8yr 
A significant 31% 
reduction in risk of stroke, 
44% reduction for coronary 
heart disease, 35% 
reduction in cardiovascular 
events, and 29% reduction 
in cardiovascular deaths in 
the diuretic arm.    
STOP-
Hypertension74  
n=1,627;             
Age:76yr, 
mean                      
Diuretic and/or  β-blocker                      
or                                       
Placebo 
Mean:25mo 
A significant 47% relative 
reduction in all type stroke, 
and 43% reduction in all-
cause mortality. 
Syst-Eur76 
n=4,695;                                
Age:70yr, 








A significant 42% 
reduction in stroke (fatal 
and non-fatal), and 26% 
reduction in fatal and non-
fatal cardiac endpoints 
(heart failure, myocardial 
infarction, and sudden 
death) rates. 
Abbreviations:  SHEP refers to Systolic Hypertension in the Elderly; MRC, Medical Research Council 
trial; STOP-Hypertension, Swedish Trial in Old Patients with Hypertension; Syst-Eur, Systolic 
Hypertension in Europe trial; n, sample size; yr, year; mo, months. 
With kind permission from Springer Science Business Media: Current Cardiovascular Risk Reports,
Evolving Concepts of Cardiovascular Disease Prevention in Older Adults, 3, 2009, 366-373, Yazdanyar






Table 1.2 Studies of Lipid Lowering Therapy with Statins for Primary Prevention 
Study Population Treatment Follow-up Summary of Results 
WOSCOPS91 
6,595 with 
hypercholesterolemia        
Age: range,  45-64 yr                          
Pravastatin 
40 mg/d           




31% reduction in non-
fatal MI or CHD 
mortality; 22% 
reduction in total 
mortality 
AFCAPS/TexCAPS88 
6,605 with average 
cholesterol levels 
(LDL-C mean, 150 
mg/dL)                     
Age: mean,58 yr;                                  
Range,  45-73 yr;                 
Included 1,416 persons 
aged ≥65 yr 
Lovastatin 
20-40 mg/d                             
or                            
Placebo 
Mean:5.2 yr 
37% reduction in fatal 
or non-fatal MI, 
unstable angina, or 
sudden death,  40% 
reduction in fatal and 
non-fatal MI, 25% 
reduction in total CV 
events, 25% reduction 
in fatal and non-fatal 
coronary events, and 
33% reduction in 
revascularizations. 
HPS87 
20,536 at high risk                                     
Age: range, 40-80 yr;    
Included 5,806 persons 
aged ≥70 yr 
Simvastatin  




reduction in rate of 
non-fatal MI or 
coronary death, fatal 
or non-fatal stroke, 





hypertension                                 
Age: mean, 63 yr;                               
range, 40-79 yr; 
Included 6,570 persons 
aged ≥60 yr    
Atorvastatin 




 36% reduction in 
endpoint of non-fatal 
MI, including silent 
MI, and fatal CHD.  
PROSPER90 
4,695 participants                               
Age: mean, 75 yr;                    
range,70-82 yr 
Pravastatin 
40 mg/d          




15% reduction in 
endpoint of coronary 
death, non-fatal MI, 
and fatal or non-fatal 
stroke. Also, a 24% 
reduction in CHD 
mortality.  No 
significant effect on 
rate of stroke, 
cognitive decline, or 
disability. 
Abbreviations: WOSCOPS refers to West of Scotland Coronary Prevention Study; AFCAPS/TexCAPS, 
Air Force/Texas Coronary Atherosclerosis Prevention Study; HPS, Heart Protection Study; PROSPER, 
Pravastatin in elderlyat risk of vascular disease; ASCOT-LLA, Anglo-Scandanavian Cardiac Outcomes
Trial-Lipid Lowering Arm;.  With kind permission from Springer Science Business Media:  Current
Cardiovascular Risk Reports, Evolving Concepts of Cardiovascular Disease Prevention in Older Adults, 3,




Table 1.3 Studies of Lipid Lowering Therapy with Statins for Secondary Prevention 
Study Population Treatment Follow-up  Summary of Results 
4S55 
4,444 participants with 
hypercholesterolemia            
Age: mean, 58 yr (men),                                                                             
 61 yr (women);                      
range, 35-74 yr;                          
Included 2,284 persons 
≥60 yr 
Simvastatin    
10-40 mg/d            
or                                          
Placebo 
Median:5.4yr 
42% relative reduction in coronary-
related mortality, 35% reduction in 
all-CVD-related mortality, and 
30% reduction in all-cause 
mortality.  Also, a 37% relative 
reduction in non-fatal MI.  Similar 
beneficial treatment effect in 
persons aged ≥60 and ≤60 years 
old. 
CARE57 
4,159 participants                      
Age: mean: 59 yr;                           
 range, 21-75 yr;                                   
Included 2,129 persons 
aged ≥60 yr 
Pravastatin        
40 mg/d             
or                                          
Placebo 
Median: 5 yr 
24% relative reduction in primary 
endpoint of fatal CHD or MI.   
LIPID56 
9,014 participants at high 
risk                                     
Age: median, 62 yr; 
 range, 31-75 yr;                            
Included 2,168 persons 
aged 65-69 yr and 1,346 
aged ≥70 yr 
Pravastatin        
40 mg/d            
or                                          
Placebo 
Mean: 6.1 yr 
A 24% reduction in CHD mortality 
and 22% reduction in all-cause 
mortality.  Also, reductions in non-
fatal MI and stroke. 
Abbreviations: 4S refers to Scandinavian Simvastatin Survival Study; CARE, Cholesterol and Recurrent 
Events trial; LIPID, Long-term Intervention with Pravastatin in Ischemia; mg/d, milligrams per day; yr, 
year.
With Kind permission from Springer Science Business Media: Current Cardiovascular Risk Reports,
Evolving Concepts of Cardiovascular Disease Prevention in Older Adults, 3, 2009, 366-373, Yazdanyar A 















Table 1.4  Relationship of Physical Activity in Older Adults with Coronary Heart Disease and Mortality 







4,174 adults aged 55 
years and older (21% 
aged 65-70 years) 
residents of Alameda 
County, California 
participating in the 
Alameda County 
Study; follow-up 








Adults aged 60 years 
or more reporting low 
compared to high 
physical activity level 
had a higher risk of 
all-cause mortality 






A total of 1,874 East 
Boston, 1488 New 
Haven, and 1,815 Iowa 
older adult (aged 65 
years and older) 




of the Elderly; 
Outcomes assessed 





such as walking. 
Frequent walking was 
associated with 
reduced risk of 
mortality over 3 and 6 
years; moderate to 
high activity reduced 
risk of physical 
limitation over 3 years; 
No significant 
relationship of activity 







A total of 802 older 
aged 64 years or more 
(mean, 71.4±5.2 years) 
Dutch men 
participating in the 
Zutphen Elderly 
Study; Outcomes 





Relative to lowest 
physical activity, 
adults in highest tertile 
had a reduced risk of 
all-cause mortality( 
HR , 0.77; 95% CI, 
0.59-1.00) and CVD 
mortality (HR, 0.70; 
95% CI, 0.48-1.01) but 
not CHD mortality 






A total of 2,357 older 
aged men (mean age, 
72 years) participating 
in the Physicians' 
Health Study 
Questionnaire of 
the frequency of 
vigorous exercise 
Regular exercise was 
associated with a 
lower risk of mortality 






A total of 1,861 aged 
70 years or more 








physical activity and 
initiating physical 
activity after age of 70 
years were associated 
with reduced risk of 
mortality. 




Table 1.5 Relationship of Treadmill and Cycle Ergometry Exercise-Based Fitness with Mortality 
Study Study Design 
Study 






aged men and 




the Cooper Clinic 
Maximal exercise 
treadmill test 
Lower risk of all-cause 
mortality primarily due to 
CVD and cancer deaths with 
higher fitness in men and 
women.  RR for 2 least-fit 
quintiles(Q) relative to most 
fit quintile in men were Q1 
1.8(95% CI,1.4-2.4) and Q2 
1.3(95% CI,1.0-1.8).  In 
women, the risk in least fit 
quintile was 3.9(95% CI,1.4-
11.0) relative to most fit 
quintile.  Decline observed in 
death rates with higher 
fitness was more pronounced 











disease in eastern 
Finland (mean 









Both exercise duration and 
oxygen uptake were 
predictors of mortality.  
Relative to MET>10.6, 
MET<7.9 was associated 
with HR 3.85 (95% CI, 2.0-
7.3) of overall death, 
3.97(95% CI,1.3-12.0) CVD-
specific death, and 3.79(95% 
CI,1.7-8.4) non-CVD deaths. 
Relative to exercise 
duration>11.2 min, 
duration<8.2 was associated 
with HR 3.94 (95% CI, 2.0-
7.7) of overall death, 
4.54(95% CI,1.5-14.0) CVD-
specific death, and 3.68(95% 
CI,1.6-8.6) non-CVD deaths. 












Table 1.5 (Continued) 





514 older adults aged 
65 years and older and 
2,593 adults aged 
younger than 65 years 
participating in the 
Rochester 
Epidemiology Project; 
48% women in 
elderly subgroup 
Treadmill 





In older adults, an 
increase of 1 MET 
associated with 18% 
decrease risk of cardiac 
events and 18% 
decreased risk of death; 
Mortality rate 37% in 







1,185 older male 
adults aged 65 years 
and older and 2,789 
adults aged 65 years 





United States Air 





In older and younger 
subgroups, an increase of 
1 MET was associated 
with 11% decrease risk 
of death; Mortality rate 
23% in older and 10% 





6,213 men referred for 
exercise testing; age 








An increase of 1 MET 
associated with 12% 
decrease risk of death; 
Annual average 







in the St James 
Women Take Heart 





An increase of 1 MET 
associated with 17% 
decrease risk of death; 







6,022 adults aged 65 
to 74 and 1,332 aged 
75 years and older 
referred for exercise 




modified Bruce,  
or Cornell 
protocol 
Impaired peak exercise 
workload in lowest 
quintile for age- and sex- 
strata (HR, 2.1; 95% CI, 
1.8 - 2.4) and impaired 
heart rate recovery (HR, 
1.5;95% CI, 1.3 - 1.7) 
were associated with 
increased mortality risk 







Table 1.5 (Continued) 
Study Study Design 
Study 













30 to 80 years age 
range  
Treadmill exercise test 
according to Bruce 
protocol 
A decrease in MET 
was associated with 
increased risk of all-
cause  (HR, 1.11; 95% 
CI , 1.06 - 1.17) and 
cardiovascular death  
(HR, 1.17; 95% CI, 
1.07 - 1.27); A 10 beat 
per minute decrement 
in heart rate recovery 
was associated with an 
increase risk of all-
cause death  (HR, 1.20; 
95% CI , 1.04 - 1.38) 
Sui et al.153 
 Retrospective 
Cohort 






Study; age 64 +/- 
5 years 
Treadmill exercise test 
according to a 
modified Balke 
protocol 
Relative to referent 
lowest quintile of 
treadmill duration, 
decreased risk of 
mortality across longer 
treadmill time 
quintiles, HR, 0.53; 
0.44, 0.43, 0.30, 
respectively; Both 









veterans aged 65 
years or more 
(mean age, 71.4 
years; 3,224 
White ad 2,090 
Black) with either 
routine evaluation 




of 8.1 years 
Treadmill exercise test 
according to either a 
Balke protocol or an 
individualized ramp 
protocol 
Compared to persons 
with fitness at 4 METs 
or less, there was 
reduces risk of 
mortality  persons 
achieving  METs 5.1-
6.0 with (HR, 0.62; 
95% CI, 0.54-0.71) 
and those achieving 
METs of 9 or more 
with HR 0.39 (95% CI, 
0.32-0.49). 








Table 1.6 Relationship between the 6 Minute Walk Test Performance with Mortality 
Study Study 
Design 




45 adults referred 
for heart 
transplantation 
evaluation; age 49 
+/- 8 years 





6 MWT distance less than 300 
meters was associated with 
short-term (6 months) death or 
hospitalization for inotropic or 
mechanical support (p=0.04) 






sample of 898 
patients with 
ejection fraction 
0.45 or less enrolled 
in the randomized 
clinical trial 
(SOLVD); age 59 
+/- 12 years 
6 MWT 
Decrement of 120 meters was 
associated with increased 
mortality in heart failure with 
ejection fraction less than 0.45 
(OR, 1.50; 95% CI, 1.11 - 2.03) 
and also among preserved 
ejection fraction (OR, 2.62; 




214 patients either 
referred or admitted 
via emergency 
department for mild 
to moderate heart 
failure; age 64 years 





6 MWT distance less than 300 
meters was associated with a 
higher risk of mortality 
(p=0.012) compared to higher 
distance walked; Multivariable 
association revealed a reduced 
risk of death per meter increase 
in walk distance (HR, 0.995; 
95% CI, 0.993 - 0.997) 
Shah et al.157 Prospective 
440 symptomatic 
heart failure with 
ejection fraction 
0.25 or less patients 







therapy alone; age 
64 years in able to 
walk and 67 years 
in unable to walk  
6 MWT 
Decrement of 100 meters 
during 6 MWT distance was 
associated with increased risk 
of mortality (HR, 0.58; 95% CI, 
0.50 - 0.68) and hospitalization 
(HR, 0.85; 95% CI, 0.46 - 0.90) 
Abbreviations: 6 MWT represents 6 Minute Walk Test; HR, hazards ratio; OR, Odds Ratio;  95% CI, 95% 




Table 1.6 (Continued) 







454 patient with 
Idiopathic Pulmonary 
Fibrosis listed for lung 
transplantation with 
United Network for Organ 
Sharing; age 56 +/- 9 
years 
6 MWT 
6 MWT distance less than 207 
meters relative to greater distance 
was associated with increased 
waiting-list mortality risk (HR, 





188 patients with 
moderate to severe heart 
failure referred for cardiac 
resynchronization therapy; 
age 69 +/- 8 years 
6 MWT 
6 MWT distance less than 225 
meters was associated with 
increased risk of mortality 
relative to a distance of 400 
meters or longer (HR, 5.6; 95% 




198 African American 
patients with acute 
decompensated heart 
failure admitted to a single 
tertiary hospital; age 56 
+/- 13 years 
6 MWT 
6 MWT distance less than 200 
meters was associated with 
increased risk of mortality (HR, 
2.1; 95% CI, 1.2 - 3.8) relative a 





815 patients with severe 
Chronic Obstructive 
Pulmonary Disease with 
inpatient pulmonary 
rehabilitation; age 73 +/- 9 
6 MWT 
Post-pulmonary rehabilitation 6 
MWT distance was associated 
with survival (HR, 1.3; 95% CI, 




121 patients with end 
stage liver disease listed 
for liver transplantation at 
a tertiary medical center; 
age 56 +/- 9 years 
6 MWT 
Increase of 100 meters on 6 
MWT distance was associated 
with lower mortality risk  (HR, 




60 patients recruited from 
a heart failure clinic; age 
78 +/- 12 years 
6 MWT 
Increase of 30 meters during 6 
MWT distance was associated 
with decreased risk of mortality 
(HR, 0.82; 95% CI 0.72 - 0.94) 
along with an increase risk 
associated with markers of frailty 
(HR, 1.64; 95% CI, 1.19 - 2.26) 
Abbreviations: HR represents hazards ratio; OR, Odds Ratio;  95% CI, 95% Confidence Interval; MET, 






























Figure 1.1 Number of Deaths (in thousands) due to Cardiovascular Diseases by Age 
in 2005 
Reprinted from Clin Geriatr Med, 29, Yazdanyar A Newman AB, The Burden of 
Cardiovascular Disease in the Elderly: Morbidity, Mortality, and Costs, 563-577, 


































































Figure 1.2  Prevalence of Cardiovascular Disease in Adults aged 20 Years and Older 
by Age and Sex 
Reprinted from Clin Geriatr Med, 29, Yazdanyar A Newman AB, The Burden of 
Cardiovascular Disease in the Elderly: Morbidity, Mortality, and Costs, 563-577,






















































Figure 1.3  Incidence of Cardiovascular Disease in Adults Aged 45 Years and Older 













































Reprinted from Clin Geriatr Med, 29, Yazdanyar A Newman AB, The Burden of
Cardiovascular Disease in the Elderly: Morbidity, Mortality, Costs, 563-577, 



























Reprinted from Clin Geriatr Med, 29, Yazdanyar A Newman AB, The Burden of 
Cardiovascular Disease in the Elderly: Morbidity, Mortality, and Costs, 563-577,

































Figure 1.4 Prevalence of Coronary Heart Disease in Adults Aged 20 Years and 

























Figure 1.5 Ten Year Incidence Rate of Coronary Heart Disease in Caucasians by 
Age and Sex: Cardiovascular Health Study 
Reprinted from Clin Geriatr Med, 29, Yazdanyar A Newman AB, The Burden of 
Cardiovascular Disease in the Elderly: Morbidity, Mortality, Costs, 563-577,








































































Figure 1.6 Incidence Rate of Coronary Heart Disease in African Americans by Age 
and Sex: Cardiovascular Health Study 
Reprinted from Clin Geriatr Med, 29, Yazdanyar A Newman AB, The Burden of Cardio- 
vascular Disease in the Elderly: Mortality, Mortality, and Costs, 563-577, Copyright 2009






























































































































Figure 1.7 Ten Year Incidence Rate of Myocardial Infarction in Causasians by Age 

























Figure 1.8 Ten Year Incidence of Myocardial Infarction in African Americans by 











































































Figure 1.9 Ten Year Incidence of Heart Failure in Caucasians by Age and Sex: 




























































































































































































































































Figure 1.12 Ten Year Incidence of Stroke in African Americans by Age and Sex: 












































































































2.0  ASSOCIATION BETWEEN SIX MINUTE WALK DISTANCE AND ALL-CAUSE 
MORTALITY, CORONARY HEART DISEASE-SPECIFIC MORTALITY, AND 
INCIDENT CORONARY HEART DISEASE 
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Introduction:  Exercise fitness assessed by treadmill exercise testing is an independent predictor 
of morbidity and mortality in middle-age and older adults.  However, little has been reported on 
the utility of submaximal walking testing, such as the six-minute walk test (6 MWT), in 
predicting outcomes among older adults.  Objective:  To determine whether the 6 MWT distance 
is an independent predictor of all-cause mortality, coronary heart disease(CHD)-specific 
mortality, and incident CHD in a large cohort of community-dwelling older adults.  Methods:  
We conducted a time-to-event analysis of the 4,708 Cardiovascular Health Study (CHS) 
participants, a well-characterized cohort of older adults from 4 U.S. communities.  The 6 MWT 
was conducted during clinic visit from June 1996 to May 1997, and completed by 2,116 
participants.  Additionally, 163 partially completed, and 1,052 did not attempt the 6 MWT test, 
while 1,377 did not have an in-person annual study exam.  Events were determined after a mean 
follow-up time of 7.3 years.  Results:  The mean age at the time of the 6 MWT was 77.4 years; 
and the mean 6MWT distance was 343.5 meters.  During follow-up, there were 793 all-cause 
deaths, and 187 CHD-specific deaths among participants with a 6 MWT.  Among the 1,822 
without prevalent CHD at the time of 6 MWT, 347 incident CHD events occurred.  Event rates 
(per 1000 person-years) were 47.6 for all-cause mortality, 11.2 for CHD-specific mortality, and 
27.6 for incident CHD.  In age- and sex-adjusted models, participants in the lowest 6 MWT 
distance quintile  (<279 meters) were at increased risk of all-cause mortality (adjusted Hazard 
Ratio (HR), 3.0; 95% Confidence Interval (CI), 2.4-3.8), CHD-specific mortality (adjusted HR, 
2.4; 95% CI, 1.5-3.8) and incident CHD (adjusted HR, 1.6; 95% CI, 1.2-2.3).  In a fully adjusted 
 53 
model, participants with a 6MWT performance in the lowest two distance quintiles remained at a 
greater risk of all-cause mortality (6 MWT 279-333 meters: adjusted HR 1.6; 95% CI, 1.2-2.2; 6 
MWT <279 meters: adjusted HR 1.9; 95% CI, 1.4-2.5).  The inverse relationship between 6 
MWT performance and all-cause mortality remained in analyses stratified by age, sex, and race. 
The increased risk of CHD-specific mortality and incident CHD  observed in the lowest 6 MWT 
distance quintile (<279 meters) was attenuated, by 65.5% and 71%, respectively, after 
adjustment for confounders (CHD-specific mortality adjusted HR, 1.4 (95% CI, 0.8-2.4); 
incident CHD adjusted HR, 1.2 (95% CI, 0.8-1.8).  Conclusion:  The 6 MWT was an 
independent predictor of all-cause mortality in community-dwelling older adults. 
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2.2 INTRODUCTION 
Physical fitness, as measured by exercise duration or oxygen uptake, has been shown to predict 
cardiovascular events and all-cause mortality in middle-aged and older adults populations1-7.   
Treadmill-based and walk-based testing represent alternate methods for the assessment of 
functional exercise capacity8.  While the treadmill exercise test has been the most commonly 
applied method for the assessment of exercise capacity, older adults encounter greater limitations 
in their ability to complete a treadmill based exercise test9.  Moreover, the submaximal 
performance during a walking test in older adults may be a better reflection of daily activities 
and a more practical method of assessment than treadmill-based protocols10-12.  While 
performance on walking test such as the 6-Minute Walk test (6 MWT) has been shown to be of 
prognostic significance in various disease-specific patient populations, there is limited 
information on the prognostic value of the 6 MWT in community-dwelling older adults. 
The 6 MWT is a simple, safe, and easily administered test which has been studied in 
various disease specific populations, such as those with pulmonary disease, heart failure, 
pacemakers, peripheral arterial disease, and organ transplant candidates13-20.  In older adult 
populations the 6 MWT is a reliable and valid measure of functional capacity21.  We investigated 
the prognostic value of the 6 MWT performance in community-dwelling older adults.  More 
specifically, we aimed to determine whether the performance distance in a 6 MWT would be 





The CHS is an observational study with the primary goal of determining the risk factors for and 
consequences of cardiovascular disease in older adults.  The design and methods of the CHS 
have been previously described elsewhere22, 23.  Briefly, 5,888 community-dwelling older adults 
were recruited for CHS, including 5,201 participants recruited in 1989-1990 and an additional 
687 minority predominant participants were recruited between 1992-1993.  Recruitment was 
from a random sample of the Health Care Finance Administration Medicare eligibility lists in 
four communities: Forsyth County, North Carolina; Sacramento County, California; Washington 
County, Maryland; and Pittsburgh(Allegheny County), Pennsylvania.  Annual clinic visits and 
semi-annual telephone and clinic contacts included standardized assessments of participant 
health history and behaviors, cardiovascular risk factors, measures of subclinical cardiovascular 
disease, cognitive and physical function.  The 6 MWT was conducted during the CHS in-person 
examination performed between June 1996 and May 1997.  The 6 MWT exclusion criteria 
included the presence of pre-test electrocardiogram (ECG) abnormalities, use of ambulatory aids, 
presence of aortic stenosis, heart rate less than 50 beats per minute or greater than 110 beats per 
minute, systolic blood pressure greater than 200 mm Hg or diastolic blood pressure greater than 
110 mm Hg, or a myocardial infarction, angioplasty, coronary artery bypass surgery, new chest 
pain, dyspnea, fainting, a resting oxygen saturation less than 90%, or at the discretion of the 
technician. Of the 4,708 participants who remained enrolled in CHS between June 1996 and May 
1997, 1,377 had a phone or proxy interview and did not have an in-person study visit.  Of the 
3,331 with an in-person study visit, there were 2116 participants who completed, 163 partially 
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completed, and 1052 were either excluded due to the above listed exclusion criteria (n=764), or 
did not attempt the 6 MWT by either refusing testing (n=39), stating physically inability (n=34), 
lacking sufficient time (n=2), at technician discretion (n=28), or providing other reasons (n=30), 
while the remaining did not participate in the 6 MWT for unknown reason (n=155). 
2.3.2 Six Minute Walk Test 
The 6 MWT was conducted according to a standard protocol similar to the American Thoracic 
Society guidelines24.  Briefly, in a 100 foot section of an internal hallway with distance marked 
every five feet by colored tape along the baseboard, participants were instructed to "walk at their 
own pace" up and down the hallway while attempting to cover as much ground as possible.  This 
was the only difference between the CHS protocol for the 6 MWT and the American Thoracic 
Society guidelines where 6 MWT participants are encouraged to "cover as much distance as 
possible in 6 minutes".  Technicians encouraged the participants with the standardized 
statements, such as "you are doing well" or "keep up the good work," but were asked not to use 
other phrases.  Participants were allowed to stop and rest during the test, but were instructed to 
resume walking as soon as they could.  If a participant stopped and refused to continue the test 
before the six minutes had elapsed, the distance walked was recorded and the walk was coded as 
a partial test.  The technician used a mechanical lap counter to count the number of laps 
completed, and an electronic timer with a buzzer that sounded the completion of the 6 minutes.  
While oxygen saturation and pulse rate were recorded prior to the exercise, the technicians did 
not walk with participants and did not record the pulse oximetry readings during the walk. 
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2.3.3 Potential Confounders 
CHS exams were extensive and included risk factors and potential confounding or mediating 
variables of age, sex, race, cigarette smoking status (current vs. former or never), education level 
(less than high school vs. more than high school), history of treated hypertension or diabetes, 
weight (kilograms), height (meters), waist circumference (cm), systolic blood pressure (mm Hg), 
total cholesterol (mg/dL), and fasting glucose (mg/dL)22.  Cognitive function was assessed with 
the Mini-Mental Status Exam25 and depressive symptoms using the Center for Epidemiological 
Studies Depression (CES-D) score26.  Also assessed were limitations in the Activities of Daily 
Living (ADL) (any vs. no limitation), Instrumental Activities of Daily Living (IADL) (any vs. no 
limitation), self-reported general health status (fair or poor vs. good, very good, or excellent 
health).  Major ECG abnormalities included ventricular conduction defects, major Q or QS 
abnormalities, minor Q or QS with ST-T-wave abnormalities, left ventricular hypertrophy, 
isolated major ST-T-wave abnormalities, atrial fibrillation, or first degree atrioventricular block 
were determined by a centralized ECG Reading Center according to a standard protocol27.  The 
ankle arm index (AAI) was measured by trained technicians according to a standard protocol28. 
Prevalent CHD, CHF, stroke, TIA, and intermittent claudication were ascertained using methods 
previously described29.  Chronic pulmonary disease was defined as a history of chronic 
bronchitis, emphysema, or asthma.  Arthritis of the knees or hips was assessed by self-report. 
2.3.4 Outcomes 
The detailed methods used by the CHS for surveillance and ascertainment of mortality and 
cardiovascular events have been previously described30.  Participants were contacted every 6 
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months in regards to interim hospitalizations and clinical visits for cardiovascular diagnoses 
including myocardial infarction (MI), angina, congestive heart failure (CHF), stroke, transient 
ischemic attack (TIA), and peripheral artery disease.  An incident coronary heart disease (CHD) 
was defined as MI, angina, or coronary revascularization.  Mortality was documented by death 
certificates, inpatient records, nursing home or hospice records, physician questionnaires, and 
autopsy reports. A CHD-specific mortality was defined to include death from CHD and sudden 
death.  All deaths and cardiovascular events were adjudicated by a CHS committee using a 
standardized protocol. 
2.3.5 Statistical Analysis 
Analysis of variance or Kruskal Wallis test for continuous variable and Chi Squared test for 
categorical variables were used to test differences in participant characteristics across the 6 
MWT completion status groups and 6 MWT distance quintiles, as appropriate.   The 6 MWT 
distance was categorized into quintiles of > 411 meters, 368 to 411 meters, 333 to 368 meters, 
279 to 333 meters, and to 279 meters.  Crude event rates for each outcome were calculated and 
reported per 1000 person-years.  Cox proportional hazard regression models were used to 
determine hazard ratios for the outcome of all-cause mortality, CHD-specific mortality, and  
incident CHD.  Hazard ratios were estimated for the 6 MWT completion status groups and 
separately per quintile of 6 MWT distance with the longest 6 MWT distance quintile (> 411 
meters) serving as the referent group.  The hazards models were initially adjusted for age and 
sex, and subsequently for other confounders in fully adjusted models.  In addition, separate 
stratified Cox proportional hazards models assessed whether the direction or magnitude of the 
association between 6 MWT performance and study endpoints varied by age (<80 vs. ≥ 80 
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years), race (white vs. non-white), sex, and self-reported general health status (fair or poor vs. 
good, very good, or excellent health).   
           Statistical analyses were conducted using STATA 11.1 (STATA Corporation, College 
Station, TX).   All reported p values are based on a two-sided test with P < 0.05 considered  
statistically significant. 
2.4 RESULTS 
Participant characteristics by clinic visit and 6 MWT status revealed that those with 6 MWT 
attempt were younger, more often men, of white race, or of higher education level; taller in 
height, of lower body weight; less reported depressive symptoms; less often report inability to 
perform any ADLS or IADLS; higher cognitive function score; and were less likely to have 
prevalent health conditions or subclinical disease compared to those without a clinic visit  
(TABLE 2.1 ).  The characteristics of participants with a 6 MWT attempt, either partial or 
complete,  is shown in TABLE 2.2.   While there was no significant difference in body weight 
across 6 MWT distance quintiles, the remaining characteristics revealed a more favorable 
characteristic profile among those with 6 MWT in the longer distance quintiles.   Participant 
characteristics among those without prevalent CHD by 6 MWT completion status and distance 
quintiles are shown in TABLE 2.3 and TABLE 2.4, respectively.  Overall, the pattern of 
association observed in participants without prevalent CHD was similar to that found among 
participants with prevalent CHD. 
Among the 4,708 participants in the study cohort, there were a total of 2,286 deaths from 
all causes of which 556 deaths were attributed to coronary heart disease.  A total of 754 incident 
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CHD events occurred during follow-up among the 3,441 participants free of prevalent CHD.  
Figures 2.1-2.6 show the Kaplan Meier survival curves for the outcomes of all-cause mortality, 
CHD-specific mortality, and incident CHD by clinic visit and 6 MWT status.  The overall all-
cause mortality rate was 74.4 per 1000 person-years and was lower among participants who 
either completed or partially completed the 6 MWT as compared to without a 6 MWT  either 
with or without a clinic visit ( TABLE 2.5).  This difference was attenuated after adjustment for 
age and sex, yet remained significant with hazard ratio greater than 1.0 for participants without a 
6 MWT  and those without a clinic visit.  After further adjustment for all potential confounders, 
the hazard ratio remained significant for participants without a clinic visit ( HR 1.9; 95% CI:1.3-
2.7) while a trend was observed for increased hazard for participants with a clinic visit but 
without a 6 MWT ( HR 1.1; 95% CI: 1.0-1.3).  The overall rate of CHD-specific mortality was 
18.1 per 1000 person-years.  A greater than two-fold CHD-specific mortality rate was observed 
in participants without a clinic visit compared to those completing a 6 MWT during their clinic 
visit.  The hazard ratio for CHD-specific mortality for was greater than 1.0 in participants 
without a 6 MWT or a clinic visit after adjusting for age and sex but no longer significant in fully 
adjusted model ( TABLE 2.5).  
 Incident CHD was evaluated among the 3,441 participants without prevalent CHD.  A 
total of 754 incident CHD events were observed over the follow-up time with an overall event 
rate of 35.1 per 1000 person-year.  Participants without a clinic visit and those with a clinic visit 
but without a 6 MWT had a nearly one and a half fold higher rate of incident CHD than those 
who had a clinic visit and either partially or fully completed the 6 MWT.  While the higher risk 
among participants without a 6 MWT with or without a clinic visit remained significant in an age 
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and sex adjusted model, after adjusting for all confounders the hazard ratios for incident CHD 
were no longer statistically significant ( TABLE2.5). 
Among 2,279 participants who attempted a 6 MWT ( TABLE 2.6 ), there were 793  
deaths due to all causes with the majority of the deaths 512(64.5%) due to non-cardiovascular 
etiology.  Of the 793 deaths, 281(35.4%) were due to cardiovascular diseases with 187(66.5%)  
secondary to coronary heart disease.   Among the participants with a 6 MWT, a distance in the 
two shortest distance quintiles (walk distance 279-333 meters and <279 meters)  was associated 
with an increased hazard of all-cause mortality relative to a 6 MWT distance >411 meters.  This 
higher risk of all-cause mortality remained in models adjusting for age and sex (walk distance 
279-333 meters; crude event rate, 58.1 vs. 27.0 per 1000 person-years; adjusted HR, 2.1; 95% 
CI, 1.7-2.7: walk distance <279 meters; crude event rate, 80.6 vs. 27.0 per 1000 person-years; 
adjusted HR, 3.0; 95% CI, 2.4-3.8).  In a fully adjusted model, participants with a 6MWT 
distance in the poorest two performance quintiles remained at higher risk of all-cause mortality 
(walk distance 279-333 meters; adjusted HR, 1.6; 95% CI, 1.2-2.2: walk distance <279 meters; 
adjusted HR, 1.9; 95% CI, 1.4-2.5).  The inverse association between 6 MWT distance and all-
cause mortality persisted in separate analyses when stratified by sex, race, age (65-80 vs. ≥80 
years), and subclinical cardiovascular disease status (either major ECG abnormality or AAI<1.0).    
In sex-stratified analysis, the multivariable adjusted hazard ratios for the association 
between 6 MWT performance and all-cause mortality in women were HR 2.0 (95% CI, 1.0-3.1) 
for 6 MWT distance 0-279 meters, HR 1.6 (95% CI, 1.0-3.0) for 279-333 meters, HR 1.1 (95% 
CI, 0.7-1.7) for 333-368 meters, and HR 1.1  (95% CI, 0.7-1.8) for 368-411 meters relative to 6 
MWT distance >411 meters. Similarly in sex-stratified analysis, the multivariable adjusted 
hazard ratios for men were HR 1.8 (95% CI, 1.2-2.7) for 6 MWT distance 0-279 meters, HR 1.7 
 62 
(95% CI, 1.2-2.7) for 279-333 meters, HR 1.5 (95% CI, 1.0-2.2) for 333-368 meters, and HR 1.2  
(95% CI, 0.8-1.8) for 368-411 meters relative to 6 MWT distance >411 meters.  In age-stratified 
analysis, the multivariable adjusted hazard ratios for the association between 6 MWT 
performance and all-cause mortality in participants aged 65-80 years were HR 1.9 (95% CI, 1.3-
2.7) for 6 MWT distance 0-279 meters, HR 1.7 (95% CI, 1.2-2.4) for 279-333 meters, HR 1.1 
(95% CI, 0.8-1.6) for 333-368 meters, and HR 1.1  (95% CI, 0.8-1.6) for 368-411 meters relative 
to 6 MWT distance >411 meters. In age-stratified analysis, the multivariable adjusted hazard 
ratios for participants aged ≥ 80 years were HR 2.5 (95% CI, 1.5-4.5) for 6 MWT distance 0-279 
meters, HR 2.1 (95% CI, 1.2-3.7) for 279-333 meters, HR 1.8 (95% CI, 1.0-3.1) for 333-368 
meters, and HR 1.3  (95% CI, 0.7-2.3) for 368-411 meters relative to 6 MWT distance >411 
meters.  In race-stratified analysis, the adjusted hazard ratios for all-cause mortality in non-
non-white participants were HR 1.5 (95% CI, 0.5-4.3) for 6 MWT distance 0-279 meters, HR
0.9 (95% CI, 0.3-2.7) for 279-333 meters, HR 0.9 (95% CI, 0.3-3.0) for 333-368 meters, and HR 
1.7  (95% CI, 0.5-5.1) for 368-411 meters relative to 6 MWT distance >411 meters. The adjusted 
risk for participants of white race was HR 1.9 (95% CI, 1.4-2.6) for 6 MWT distance 0-279 
meters, HR 1.7 (95% CI, 1.3-2.3) for 279-333 meters, HR 1.3 (95% CI, 0.9-1.7) for 333-368 
meters, and HR 1.1  (95% CI, 0.8-1.5) for 368-411 meters relative to 6 MWT distance >411 meters.  
Persons reporting a good or excellent general health had an adjusted HR 3.5 (95% CI, 1.4-9) for 6
MWT 0-279 meters, HR 2.3 (95% CI, 0.9-6.2) for 279-333 meters, HR 1.5 (95% CI, 0.6-4.2) for 
333-368 meters, and HR 1.9 (95% CI, 0.7-5) for 368-411 meters relative to a 6 MWT > 411 meters.
Those reporting poor or fair health had a HR 1.8 (95% CI, 1.3-2.5) for 6 MWT 0-279 meters, HR 1.8 
(95% CI, 1.3-2.4) for 279-333 meters, HR 1.3 (95% CI, 0.9-1.8) for 333-368 meters, and HR 1.1 
(95% CI, 0.8-1.5) for 368-411 meters relative to a 6 MWT distance > 411 meters.
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           Of 793 all-cause deaths among the 2,279 with a 6 MWT, 187(23.6%) were attributed to CHD 
 
with an overall CHD-specific death rate of 11.2 per 1,000 person-years.  A 6 MWT distance in the 
shortest two quintiles was associated with a greater than 1.5-fold unadjusted CHD-death risk relative
to 6 MWT performance >411 meters.  After adjusting for age and sex, the two shortest 6 MWT  
quintiles remained at higher risk for CHD-specific mortality (walk distance 279-333 meters; 
crude event rate, 13.9 vs. 8.4 per 1000 person-years; adjusted HR, 1.8; 95% CI, 1.1-2.8: walk 
distance <279 meters; crude event rate, 18.2 vs. 8.4 per 1000 person-years; adjusted HR, 2.4; 
95% CI, 1.5-3.8).  Further adjustment for prevalent medical conditions and limitations in daily 
activities resulted in an attenuation of CHD-specific mortality risk observed in the 6 MWT 
distance 279-333 meters ( adjusted HR, 1.4; 95% CI, 0.8-2.4) while there remained a higher risk 
of CHD-specific mortality for 6 MWT distance <279 meters (adjusted HR, 1.8; 95% CI, 1.0-3.1).     
In  the fully adjusted model, the CHD-specific mortality risk associated with the two poorest 6 
MWT distance quintiles was further attenuated (walk distance 279-333 meters; adjusted HR, 1.1; 




            Three hundred and forty-seven incident CHD events occurred among the 1,822 persons
 with a 6 MWT with an overall incident CHD rate of 27.6 per 1000 person-years.    A  6  MWT
distance in the poorest 6 MWT distance < 279 meters was associated with a higher risk of 
incident CHD (adjusted HR, 1.6; 95% CI, 1.1-2.3).  In an age- and sex- adjusted model, a 6 
MWT distance < 279 meters remained associated with an increased risk of incident CHD; crude 
event rate, 37.9 vs. 24.5 per 1000 person-years; adjusted HR, 1.6; 95% CI, 1.1-2.3).  Further 
adjustment for anthropometric measures, including waist circumference, weight, and height, 
(adjusted HR, 1.4; 95% CI, 0.9-2.0) and in a fully adjusted model (adjusted HR, 1.2; 95% CI, 0.8-
1.8) the risk of incident CHD associated with the shortest 6 MWT quintiles was further attenuated.
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2.5 DISCUSSION 
In a cohort of community-dwelling older adults, both the performance distance walked and 
participation in a 6 Minute Walk test were shown to be independent predictors of all-cause 
mortality.  The 6 MWT distance was shown to have a strong graded relationship with all-cause 
mortality.  Among participants with a 6 MWT distances between 279-333 meters and <279 
meters, the relative risk of all-cause mortality was 63% and 89% greater than participants able to 
walk >411 meters.  The 6 MWT was also associated with CHD outcomes but this association 
was explained by poorer participant health status.  This study suggests the 6MWT is a useful 
measure of functional exercise capacity with prognostic significance and extends previous work 
in specific patient populations to community-dwelling older adults with a wide range of 
performance. 
Performance on walk-based testing has been shown to be correlated with 
cardiorespiratory fitness31.  In addition, both self-reported walking ability and performance on 
distance-based walk tests have been shown to be predictors of disability, cardiovascular 
morbidity, and all-cause mortality32-34.  Performance on the Long Distance Corridor Walk 
(LDCW), a distance-based walking test, has been previously shown to be prognostic of 
morbidity and mortality in older adults33. While distance-based walking tests have the advantage 
of providing participants with motivation in order to maintain a faster gait speed, they are limited 
in their ability of capturing the performance of persons who fail to complete the full distance of 
the test35,36.  In contrast, time-based walking tests, such as the 6 MWT, allow the capture of 
performance by all who are tested regardless of whether the participant walked for the full 
allotted time period.  This unique advantage of time-based walking tests allows the capturing of 
walking distance of those with very low level of walking performance.  As for the relationship 
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between the 6 MWT and health outcomes, the inverse association has previously been 
demonstrated in disease-specific populations, including patients with heart failure, pulmonary 
disease, and end stage liver disease37-41.  More recently a smaller study of 217 Finish women 
examined the relationship of 6 MWT performance and participation with all-cause mortality and 
found that participating in a 6 MWT to be a significant predictor of mortality42.   
Several strength and limitations of our study noteworthy.  First, the performance during a 
6 MWT may not reflect an individual's maximal oxygen uptake.  Second, approximately one-
third of the participants with a clinic visit did not perform a 6 MWT and in separate analyses we 
did reveal that lack of participation in the clinic visit and 6 MWT was prognostic.  The strengths 
of our study include its large sample size, long follow-up time, standardized surveillance and 
ascertainment of hard outcomes, and a cohort of older adults with a wide spectrum of function 
and health condition. 
The conventional method for the assessment of cardiorespiratory or exercise capacity is 
via exercise treadmill testing and our finding of an inverse relationship between all-cause 
mortality and functional exercise capacity is consistent with well-established literature using 
treadmill-based measurement of exercise capacity2-7, 43.  Although the treadmill exercise test is 
considered the "gold standard", it has several limitations including requiring clinical oversight by 
trained personnel, has associated equipment costs, and safety concerns.  Alternatively, the 6 
MWT is a valid and reliable method of physical endurance assessment which can be performed 
by many older adults21,44.  Our findings suggests that the 6-Minute Walk test, as a measure of 




2.6       REFERENCES FOR CHAPTER 2 
1. Blair SN, Kampert JB, Kohl HW, 3rd, et al. Influences of cardiorespiratory fitness and 
other precursors on cardiovascular disease and all-cause mortality in men and women. 
JAMA. Jul 17 1996;276(3):205-210. 
 
2. Goraya TY, Jacobsen SJ, Pellikka PA, et al. Prognostic value of treadmill exercise testing 
in elderly persons. Ann Intern Med. Jun 6 2000;132(11):862-870. 
 
3. Gulati M, Pandey DK, Arnsdorf MF, et al. Exercise capacity and the risk of death in 
women: the St James Women Take Heart Project. Circulation. Sep 30 
2003;108(13):1554-1559. 
 
4. Messinger-Rapport B, Pothier Snader CE, Blackstone EH, Yu D, Lauer MS. Value of 
exercise capacity and heart rate recovery in older people. J Am Geriatr Soc. Jan 
2003;51(1):63-68. 
 
5. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and 
mortality among men referred for exercise testing. N Engl J Med. Mar 14 
2002;346(11):793-801. 
 
6. Spin JM, Prakash M, Froelicher VF, et al. The prognostic value of exercise testing in 
elderly men. Am J Med. Apr 15 2002;112(6):453-459. 
 
7. Sui X, Laditka JN, Hardin JW, Blair SN. Estimated functional capacity predicts mortality 
in older adults. J Am Geriatr Soc. Dec 2007;55(12):1940-1947. 
 
8. Fleg JL, Pina IL, Balady GJ, et al. Assessment of functional capacity in clinical and 
research applications: An advisory from the Committee on Exercise, Rehabilitation, and 
Prevention, Council on Clinical Cardiology, American Heart Association. Circulation. 
Sep 26 2000;102(13):1591-1597. 
 
9. Gill TM, DiPietro L, Krumholz HM. Role of exercise stress testing and safety monitoring 
for older persons starting an exercise program. JAMA. Jul 19 2000;284(3):342-349. 
 
10. Greig C, Butler F, Skelton D, Mahmud S, Young A. Treadmill walking in old age may 
not reproduce the real life situation. J Am Geriatr Soc. Jan 1993;41(1):15-18. 
 
11. Hollenberg M, Ngo LH, Turner D, Tager IB. Treadmill exercise testing in an 
epidemiologic study of elderly subjects. J Gerontol A Biol Sci Med Sci. Jul 
1998;53(4):B259-267. 
 
12. Peeters P, Mets T. The 6-minute walk as an appropriate exercise test in elderly patients 
with chronic heart failure. J Gerontol A Biol Sci Med Sci. Jul 1996;51(4):M147-151. 
 67 
13. Bernstein ML, Despars JA, Singh NP, Avalos K, Stansbury DW, Light RW. Reanalysis 
of the 12-minute walk in patients with chronic obstructive pulmonary disease. Chest. Jan 
1994;105(1):163-167. 
 
14. Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6-
minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. 
JAMA. Oct 13 1993;270(14):1702-1707. 
 
15. Cahalin L, Pappagianopoulos P, Prevost S, Wain J, Ginns L. The relationship of the 6-
min walk test to maximal oxygen consumption in transplant candidates with end-stage 
lung disease. Chest. Aug 1995;108(2):452-459. 
 
16. Cahalin LP, Mathier MA, Semigran MJ, Dec GW, DiSalvo TG. The six-minute walk test 
predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest. 
Aug 1996;110(2):325-332. 
 
17. Langenfeld H, Schneider B, Grimm W, et al. The six-minute walk--an adequate exercise 
test for pacemaker patients? Pacing Clin Electrophysiol. Dec 1990;13(12 Pt 2):1761-
1765. 
 
18. Milligan NP, Havey J, Dossa A. Using a 6-minute walk test to predict outcomes in 
patients with left ventricular dysfunction. Rehabil Nurs. Jul-Aug 1997;22(4):177-181. 
 
19. Montgomery PS, Gardner AW. The clinical utility of a six-minute walk test in peripheral 
arterial occlusive disease patients. J Am Geriatr Soc. Jun 1998;46(6):706-711. 
 
20. Wijkstra PJ, TenVergert EM, van der Mark TW, et al. Relation of lung function, maximal 
inspiratory pressure, dyspnoea, and quality of life with exercise capacity in patients with 
chronic obstructive pulmonary disease. Thorax. May 1994;49(5):468-472. 
 
21. Rikli R, Jones C. The reliability and validity of a 6-Minute Walk test as a measure of 
physical endurance in older adults. J Aging and Phys Activity. 1998(6):363-375. 
 
22. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and 
rationale. Ann Epidemiol. Feb 1991;1(3):263-276. 
 
23. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment 
of adults 65 years and older as participants in the Cardiovascular Health Study. Ann 
Epidemiol. Jul 1993;3(4):358-366. 
 
24. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. Jul 1 
2002;166(1):111-117. 
 
25. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for 
grading the cognitive state of patients for the clinician. J Psychiatr Res. Nov 
1975;12(3):189-198. 
 68 
26. Orme JG, Reis J, Herz EJ. Factorial and discriminant validity of the Center for 
Epidemiological Studies Depression (CES-D) scale. J Clin Psychol. Jan 1986;42(1):28-
33. 
 
27. Blackburn H. Classification of the electrocardiogram for population studies: Minnesota 
Code. J Electrocardiol. Jul 1969;2(3):305-310. 
 
28. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of 
atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) 
Collaborative Research Group. Circulation. Sep 1993;88(3):837-845. 
 
29. Psaty BM, Kuller LH, Bild D, et al. Methods of assessing prevalent cardiovascular 
disease in the Cardiovascular Health Study. Ann Epidemiol. Jul 1995;5(4):270-277. 
 
30. Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of cardiovascular 
events. The Cardiovascular Health Study. Ann Epidemiol. Jul 1995;5(4):278-285. 
 
31. Simonsick EM, Fan E, Fleg JL. Estimating cardiorespiratory fitness in well-functioning 
older adults: treadmill validation of the long distance corridor walk. J Am Geriatr Soc. 
Jan 2006;54(1):127-132. 
 
32. Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery 
assessing lower extremity function: association with self-reported disability and 
prediction of mortality and nursing home admission. J Gerontol. Mar 1994;49(2):M85-
94. 
 
33. Newman AB, Simonsick EM, Naydeck BL, et al. Association of long-distance corridor 
walk performance with mortality, cardiovascular disease, mobility limitation, and 
disability. JAMA. May 3 2006;295(17):2018-2026. 
 
34. Vestergaard S, Patel KV, Bandinelli S, Ferrucci L, Guralnik JM. Characteristics of 400-
meter walk test performance and subsequent mortality in older adults. Rejuvenation Res. 
Jun 2009;12(3):177-184. 
 
35. Simonsick EM, Montgomery PS, Newman AB, Bauer DC, Harris T. Measuring fitness in 
healthy older adults: the Health ABC Long Distance Corridor Walk. J Am Geriatr Soc. 
Nov 2001;49(11):1544-1548. 
 
36. Swinburn CR, Wakefield JM, Jones PW. Performance, ventilation, and oxygen 
consumption in three different types of exercise test in patients with chronic obstructive 
lung disease. Thorax. Aug 1985;40(8):581-586. 
 
37. Alahdab MT, Mansour IN, Napan S, Stamos TD. Six minute walk test predicts long-term 
all-cause mortality and heart failure rehospitalization in African-American patients 
hospitalized with acute decompensated heart failure. J Card Fail. Mar 2009;15(2):130-
135. 
 69 
38. Boxer R, Kleppinger A, Ahmad A, Annis K, Hager D, Kenny A. The 6-minute walk is 
associated with frailty and predicts mortality in older adults with heart failure. Congest 
Heart Fail. Sep-Oct;16(5):208-213. 
 
39. Carey EJ, Steidley DE, Aqel BA, et al. Six-minute walk distance predicts mortality in 
liver transplant candidates. Liver Transpl. Dec;16(12):1373-1378. 
 
40. Castel MA, Mendez F, Tamborero D, et al. Six-minute walking test predicts long-term 
cardiac death in patients who received cardiac resynchronization therapy. Europace. Mar 
2009;11(3):338-342. 
 
41. Enfield K, Gammon S, Floyd J, et al. Six-minute walk distance in patients with severe 
end-stage COPD: association with survival after inpatient pulmonary rehabilitation. J 
Cardiopulm Rehabil Prev. May-Jun;30(3):195-202. 
 
42. Mutikainen S, Rantanen T, Alen M, et al. Walking Ability and All-Cause Mortality in 
Older Women. Int J Sports Med. Dec 16. 
 
43. Mora S, Redberg RF, Cui Y, et al. Ability of exercise testing to predict cardiovascular 
and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research 
clinics prevalence study. JAMA. Sep 24 2003;290(12):1600-1607. 
 
44. Enright PL, McBurnie MA, Bittner V, et al. The 6-min walk test: a quick measure of 


























































No Visit,     





Age, yr 77.4±4.3 77.9±4.5 79.0±5.3 80.7±5.8 <.001 
Male  853(40.3) 54(33.1) 425(40.4) 483(35.1) .004 
Non-white  305(14.4) 34(20.9) 22(21.6) 252(18.3) <.001 
Education(< high school) 472(22.3) 37(22.7) 283(26.9) 492(35.7) <.001 
Body mass index, kg/m2 26.7±4.2 27.8±6.0 27.2±5.2 26.7±5.7 .07 
Weight, kg 72.0±13.6 73.5±17.4 72.9±15.6 68.6±16.8 0.001 
Height, m 1.6±0.1 1.6±0.1 1.6±0.1 1.6±0.1 <.001 
SBP, mm Hg 136.0±19.4 133.9±19.4 138.6±23.1 138.9±20.5 .01 
CHD 413(19.5) 44(27.0) 344(32.7) 466(33.8) <.001 
CHF 114(5.4) 10(6.1) 161(15.3) 252(18.3) <.001 
Stroke 78(3.7) 9(5.5) 115(10.9) 187(13.6) <.001 
TIA 59(2.8) 9 (5.5) 53(5.0) 88(6.4) <.001 
Claudication 47(2.2) 9(5.5) 45(4.3) 77(5.6) <.001 
Diabetes 281(13.3) 24(14.7) 177(16.8) 115(8.4) <.001 
Arthritis  576(28.5) 57(36.5) 426(42.7) 293(37.5) <.001 
Pulmonary disease 260(12.7) 31(19.6) 178(17.6) 127(15.7) .001 
Any ADL limitation 231(11.0) 17(10.6) 348(34.4) 292(42.3) <.001 
Any IADL limitation 504(23.8) 52(31.9) 534(51.5) 385(54.7) <.001 
Current Smoker 134(6.4) 19(11.9) 88(8.6) 72(9.1) .01 
Fair or Poor Health 263(12.6) 34(20.9) 303(29.3) 416(38.8) <.001 
CES-Depression  5.2±4.4 5.9±4.6 7.1±5.3 7.1±6.2 <.001 
Mini-MMSE  93.2±7.5 91.4±10.4 88.2±13.5 75.1±21.8 <.001 
Major ECG Abnormality 598(28.8) 60(37.5) 433(42.8) 174(54.9) <.001 
AAI (< 1.0) 303(15.0) 34(21.8) 216(22.1) 283(29.3) <.001 
Total cholesterol, mg/dL 202.4±39.1 196.3±36.0 201.7±40.5 204.5±45.4 .22  
Fasting glucose, mg/dL 104.7±28.8 109.2±37.7 109.0±36.2 115.3±41.2 .001  
Medication use       
     Aspirin 120(5.7) 8(4.9) 77(7.4) 70(8.2) .04  
     Any anti-hypertensive 1106(52.3) 98(60.1) 710(67.9) 533(62.2) <.001  
     Any Lipid Lowering 254(12.0) 22(13.5) 105(10.0) 65(7.6) .003  
* Presented as mean ± SD or n(%). 
Abbreviations: 6 MWT refers to 6 Minute Walk Test; yr, year; SBP, systolic blood pressure; CHD, coronary heart 
disease; CHF, congestive heart failure; TIA, transient ischemic attack; ADL, activities of daily living; IADL, 

















(368 - 411) 
n= 462 
(333 - 368) 
n= 455 
(279 - 333) 
n= 454 




Age, yr 76.2±3.3 76.8±4.0 77.3±4.2 78.1±4.4 78.8±5.0 .001 
Male  243 (52.0) 199 (44.6) 175 (38.5) 153 (33.5) 137 (30.2) <.001 
Nonwhite  37 (7.9) 57 (12.8) 74 (16.3) 82 (17.9) 89 (19.6) <.001 
Education(<high school) 56(12.0) 83 (18.6) 103 (22.6) 130 (28.5) 137 (30.2) .001 
Body mass index, kg/m2 25.8±3.4 26.4±3.8 26.7±4.0 27.3±4.6 27.6±5.4 <.001 
Weight, kg, 72.2±12.7 72.1±13.4 72.1±13.2 72.1±14.0 71.8±16.2 0.70 
Waist Size, cm 93.7±10.9 96.0±11.8 95.7±11.7 98.1±12.9 99.2±14.6 .001 
Height, m 1.7±0.1 1.6±0.1 1.6±0.1 1.6±0.1 1.6±0.1 <.001 
Systolic blood pressure 133.5±18.3 136.4±18.5 135.3±19.7 136.4±19.0 137.7±21.3 .02 
CHD 88(18.8) 77(17.3) 85(18.7) 100(21.9) 107(23.6) .11 
CHF 19 (4.1) 18 (4.0) 16 (3.5) 30(6.6) 41(9.0) .001 
Stroke 8 (1.7) 13 (2.9) 12 (2.6) 23 (5.0) 31(6.8) <.001 
TIA 8(1.7) 11(2.5) 13(2.9) 13(2.8) 23(5.1) .04 
Claudication 3 (0.6) 10(2.2) 7(1.5) 10(2.2) 26(5.7) <.001 
Diabetes 40(8.6) 61(13.7) 63(13.9) 61(13.4) 80(17.6) .002 
Arthritis  99(22.4) 85(20.1) 119(27.6) 171(38.7) 159(36.6) <.001 
Pulmonary disease 55(12.2) 45(10.3) 38(8.7) 73(16.7) 80(18.2) <.001 
Any ADL limitation 22 (4.7) 37 (8.3) 47(10.4) 62 (13.8) 80(18.1) <.001 
Any IADL limitation 53 (11.4) 70(15.7) 108(23.7) 145(31.8) 180(39.7) <.001 
Current Smoking 21(4.6) 29(6.6) 33(7.3) 30(6.7) 40(9.0) .12 
Fair or Poor Health 23(4.9) 33(7.5) 61(13.5) 72(16.0) 108(24.0) <.001 
CES-Depression  4.2±3.9 4.6±4.1 5.5±4.6 5.6±4.7 6.2±4.9 <.001 
Mini-MMSE  95.9±4.8 93.9±6.8 93.5±7.1 92.0±8.1 90.1±9.9 <.001 
Major ECG Abnormality 114(25.0) 115(26.2) 124(28.1) 142(31.6) 163(36.4) .001 
AAI (< 1.0) 30(6.6) 46(10.8) 54(12.4) 87(20.2) 120(27.9) <.001 
Total cholesterol, mg/dL 195.7±37.8 204.3±40.3 202.2±36.9 206.1±38.1 201.5±41.0 .001 
Fasting glucose, mg/dL 100.1±22.6 103.3±26.0 106.0±30.7 106.5±31.3 109.1±34.8 .001 
Medication use       
     Aspirin 24(5.1) 26(5.8) 25(5.5) 30(6.6) 23(5.1) .86 
     Any anti-hypertensive 196(42.4) 215(48.2) 246(54.1) 246(53.8) 299(65.9) <.001 
     Any Lipid Lowering 62(13.2) 51(11.4) 59(12.9) 57(12.5) 47(10.4) .65 
* Presented as mean ± SD or n(%). 
Abbreviations: 6 MWT refers to 6 Minute Walk Test; yr, year; SBP, systolic blood pressure; CHD, coronary heart 
disease; CHF, congestive heart failure; TIA, transient ischemic attack; ADL, activities of daily living; IADL, 





























Age, yr 77.3±4.3  77.6±4.5  79.0±5.2  80.4±5.9  <.001 
Male gender 614(36.1) 35(29.4) 264(37.3) 278(30.5) .01 
Nonwhite  260(15.3) 25(21.0) 156(22.0) 175(19.2) .0004 
Education(<high school) 375(22.0) 24(20.2) 188(26.6) 305(33.5) <.001 
Body mass index, kg/m2 26.7±4.2 27.7±6.1 27.5±5.5 26.4± 5.6 .03 
Weight, kg 71.5±13.5 73.3±18.4 73.3±16.1 67.4±16.2 <.001 
Height, m 1.6±0.1 1.6±0.1 1.6±0.1 1.6±0.1 .001 
Waist size, cm 96.3±12.4 98.4±17.1 98.6±15.3 98.2±14.7 .01 
SBP, mm Hg 136.4±19.5 133.8±18.6 139.2±22.1 140.1±20.7 .002 
CHF 45(2.6) 1(0.8) 53(7.5) 79(8.7) <.001 
Stroke 46(2.7) 4(3.4) 61(8.6) 100(11.0) <.001 
TIA 40(2.4) 5(4.2) 30(4.2) 38(4.2)         .03 
Claudication 25(1.5) 4(3.4) 16(2.3) 24(2.6) .13 
Diabetes 201(11.8) 13(10.9) 116(16.4) 63(6.9) <.001 
Arthritis  449(27.7) 41(35.7) 295(43.8) 177(34.1) <.001 
Pulmonary disease 208(12.7) 25(21.4) 114(16.6) 74(13.8) .01 
Any ADL limitation 185(11.0) 14(11.9) 232(34.2) 178(38.4) <.001 
Any IADL limitation 380(22.3) 35(29.4) 341(49.0) 245(51.9) <.001 
Current Smoking 114(6.8) 14 (12.1) 65(9.3) 55(10.3) .01 
Fair or Poor health 188(11.1) 21(17.7) 181(26.1) 235(33.2) <.001 
CES-Depression 5.0±4.4 5.8±4.7 7.0±5.3 7.1±6.1 <.001 
Mini-MMSE  93.2±7.4 91.9±10.8 88.2±14.2 74.3±23.1 <.001 
Major ECG Abnormality 402(24.0) 32(27.1) 239(34.7) 91(45.5) <.001 
AAI (< 1.0) 212(13.1) 22(19.1) 117(17.7) 171(26.6) <.001 
Total cholesterol, mg/dL 203.8±38.6 196.5±38.0 202.2±41.7  211.0±44.3  .03 
Fasting glucose, mg/dL 103.3±27.2 105.2±34.0  109.0±37.0  110.3±33.6  .02 
Medication use      
     Aspirin 72(4.2) 4(3.4) 38(5.4) 36(6.2) .18 
     Any anti-hypertensive 803(47.2) 60(50.4) 413(58.8) 314(54.4) <.001 
     Any Lipid Lowering 146(8.6) 15(12.6) 43(6.1) 31(5.4) .01 
* Presented as mean ± SD or n(%). 
Abbreviations: 6 MWT refers to 6 Minute Walk Test; yr, year; SBP, systolic blood pressure; CHD, coronary heart 
disease; CHF, congestive heart failure; TIA, transient ischemic attack; ADL, activities of daily living; IADL, 








Table 2.4 Characteristics of participants without prevalent CHD by quintile (range in parentheses) of 





(368 - 411) 
n= 369 
(333 - 368) 
n= 370 
(279 - 333) 
n= 357 




Age, yr 76.1±3.4 76.6±3.9 77.2±4.1 78.1±4.4 78.6±5.0 <.001 
Male  180 (47.9) 145 (39.5) 129 (35.3) 102 (29.0) 58 (23.9) <.0001 
Nonwhite  28 (7.5) 47 (12.8) 65 (17.8) 67 (19.0) 53 (21.8) <.0001 
Education(< high school) 43(11.4) 70 (19.1) 86 (23.6) 96 (27.2) 80 (32.9) <.0001 
Body mass index, kg/m2 25.6±3.4 26.4±3.8 26.7±4.0 27.5 ± 4.6 27.7 ±5.4 <.001 
Waist size, cm 93.4±10.9  95.9±11.9 95.3±12.0  98.5±13.2 99.3±14.9 <.001 
Weight, kg  71.2±12.5 71.5±13.3 71.4±13.1 72.3±14.1 71.6±16.3 0.88 
Height, m  1.7±0.1 1.6±0.1 1.6±0.1 1.6±0.1 1.6±0.1 <.001 
SBP, mm Hg 133.3±18.5 136.6±18.5 135.8±19.6 137.0±18.7 138.9±21.6 .001 
CHF 5(1.3) 6(1.6) 7(1.9) 9(2.5) 19(7.5)     .01 
Stroke 2(0.5) 9(2.4) 7(1.9) 16(4.5) 16(4.6)  .001 
TIA 8(2.1) 7(1.9) 10(2.7) 6(1.7) 9(4.0)  .31 
Claudication 2(0.5) 4 (1.1) 4(1.1) 5(1.4) 14(4.0) .01 
Diabetes 25(6.6) 49(13.3) 44(11.9) 41(11.5) 55(15.9)  .002 
Arthritis  74(20.6) 69(19.9) 95(27.2) 131(37.6) 121(36.2) <.001 
Pulmonary disease 60(12.9) 34(9.5) 29(8.2) 60(17.6) 63(18.7) . <.001 
Any ADL limitation  18(4.8) 30(8.1) 39(10.6) 47(13.4) 65(19.2) <.001 
Any IADL limitation  40(10.6) 52(14.1) 82(22.2) 108(30.3) 133(38.3) <.001 
Current Smoking 16(4.3) 26(7.2) 33(9.0) 25(7.2) 28(6.3) .13 
Fair or Poor health 15(4.0) 23(6.3) 49(13.3) 47(13.4) 75(21.9) <.001 
CES-Depression  4.3±4.0 4.6±4.1 5.3±4.4 5.4±4.5 6.0±4.9 <.001 
Mini-MMSE  95.9±4.9 93.7±7.1 93.5±6.8 92.1±8.2 90.3±9.8 <.001 
Major ECG Abnormality 81(21.5) 76(20.8) 87(24.2) 88(25.1) 102(29.7) .05 
AAI (< 1.0)  18(4.9) 29(8.2) 40(11.4) 60(18.0) 87(26.5) <.001 
Total cholesterol, mg/dL  197.5±36.4 205.1±39.6 203.6±37.1 207.1±37.4 203.7±42.0 .01 
Fasting glucose, mg/dL  99.4±22.6 102.8±25.5 104.5±30.2 103.7±25.2 106.8±33.3 .02 
Medication use        
     Aspirin 13(3.4) 14(3.8) 15(4.1) 18(5.0) 16(4.6) .83 
     Any anti-hypertensive 141(37.2) 161(43.6) 182(49.2) 169(47.3) 210(60.52) <.001 
     Any Lipid Lowering 33(8.7) 28(7.6) 37(10.0) 31(8.7) 32(9.2) .84 
* Presented as mean ± SD or n(%). 
Abbreviations: 6 MWT refers to 6 Minute Walk Test; yr, year; SBP, systolic blood pressure; CHD, coronary 
heart disease; CHF, congestive heart failure; TIA, transient ischemic attack; ADL, activities of daily living; 
IADL, independent activities of daily living; MMSE, Mini-Mental Status Exam; ECG, electrocardiogram; AAI, 






Table 2.5 Event Rates and Hazard Ratios for Total Mortality, CHD-Specific Mortality, and Incident CHD 
Events by Visit and 6 Minute Walk Test Status 
 


















 All-Cause Mortality 4,708 2,286 74.4    
 























 Visit, Complete 6MWT 2,116 726 46.7 1.0 1.0 1.0 
 CHD-Specific Mortality 4,708 556 18.1    
 























 Visit, Complete 6MWT 2,116 173 11.1 1.0 1.0 1.0 
 Incident CHD 3,441 754 35.1    
 























 Visit, Complete 6MWT 1,703 327 27.7 1.0 1.0 1.0 
 
* Adjusted for age, sex, race, general health status, education level, smoking status, systolic blood pressure, total 
cholesterol, fasting glucose, waist circumference, height, weight, prevalent medical conditions (coronary heart 
disease, transient ischemic attack, stroke, congestive heart failure, intermittent claudication, pulmonary disease, 
diabetes mellitus, arthritis), any difficulty in Activities of Daily Living  or Instrumental Activities of Daily 
Living, CES-Depression scale score, Modified Mini-Mental State score, major electrocardiogram abnormalities, 
ankle-brachial index, and medication use (aspirin, any lipid lowering, any anti-hypertensive). 
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Table 2.6 Event Rates and Hazard Ratios for Total Mortality, CHD-Specific Mortality, and 
Incident CHD by Quintile of Six Minute Walk Test Distance 



















All-cause Mortality 2,279 793 47.6    
>411 448 100 27.0 1.0 1.0 1.0 






























2,279 187             11.2      
>411 448 31 8.4 1.0 1.0 1.0  
































Incident CHD 1,822 347 27.6     
>411 379 69 24.5 1.0 1.0 1.0  
































* Adjusted for age, sex, race, general health status, education level, smoking status, systolic blood 
pressure, total cholesterol, fasting glucose, waist circumference, height, weight, prevalent medical 
conditions (coronary heart disease, transient ischemic attack, stroke, congestive heart failure, 
intermittent claudication, pulmonary disease, diabetes mellitus, arthritis), any difficulty in 
Activities of Daily Living  or Instrumental Activities of Daily Living, CES-Depression scale 
score, Modified Mini-Mental State score, major electrocardiogram abnormalities, ankle-brachial 




2.8  FIGURES FOR CHAPTER 2 
    
 
Figure 2.1 Kaplan Meier Survival Estimates of All-Cause Mortality by Clinic Visit and Six 
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Figure 2.2 Kaplan Meier Survival Estimate of Coronary Heart Disease-Specific 
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Figure 2.3 Kaplan Meier Survival Estimate of Incident Coronary Heart Disease by Clinic 
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Figure 2.5 Kaplan Meier Survival Estimate of Coronary Heart Disease-Specific Mortality by 
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Figure 2.6 Kaplan Meier Survival Estimate of Incident Coronary Heart Disease by Quintiles of  
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3.0  ASSOCIATION BETWEEN CORONARY ARTERY CALCFICATION AND 
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3.1 ABSTRACT 
Background: While testing for treadmill exercise capacity and coronary artery 
calcification(CAC) assessment are utilized in cardiovascular risk stratification, there is limited 
information on whether these two measures are associated in the very old as they are in the 
younger adults.  Aim: To assess the relationship between physiologic and electrocardiographic 
measures based on exercise testing with CAC in a cohort of community-dwelling older adults 
without known clinical cardiovascular disease.  Additionally, we sought to determine the 
characteristics of older adults associated with a more favorable performance as measured by the 
duration of exercise on treadmill testing.  Methods:  Between 2001 and 2003, 131 of 614 
participants from the Arterial Calcification in the Elderly in Cardiovascular Health Study (ACE-
CHS) without cardiovascular disease underwent both an Electron Beam Computed Tomography 
(EBT) scan and an treadmill exercise test according to a modified Balke protocol.  Non-
participants had prevalent cardiovascular disease(n=289), did not meet additional eligibility 
criteria(n=92), had interim medical illness(n=1), incomplete data(n=1), died(n=6), or refused 
participation(n=92). The CAC was measured with EBT scanning and the physiologic and 
electrocardiographic parameters during treadmill testing.  Participant characteristics were 
compared by tertiles of treadmill exercise time.   The association between physiologic and 
electrocardiographic findings during exercise testing across CAC score tertiles were investigated.  
Logistic regression determined factors associated with the outcomes of interest, including an 
exercise-induced ischemia as detected by an electrocardiogram and also a longer time on 
treadmill exercise testing.  Results:  The mean age of participants was 82.15±3.19 years. The 
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mean treadmill exercise time was 4.55±2.71 minutes; the mean CAC score was  498±760 (range: 
0-4210). Overall, 10 (7.73%) participants had a ischemia by electrocardiogram during exercise 
treadmill testing.  Relative to participants with CAC<400, those with a CAC ≥400 had a greater 
odds of  ischemia as detected  by an electrocardiogram after adjusting for potential confounders 
(Odds Ratio [OR] 8.86;95% Confidence Interval[CI]: 1.68-46.70).  While the treadmill exercise 
duration did not differ significantly across CAC tertiles, the presence of hypertension (OR 
0.42;95% CI:0.19-0.92) and distance walked in six minutes (240 - 336 meters(m): OR 1.00 
(referent); 337- 389 m: OR 3.09 (95%CI:1.07-8.83); 390 -561 m: OR 4.47 (95% CI: 1.54-12.96)) 
were independently associated with treadmill exercise time.  Conclusion:  In a cohort of 
community-dwelling older adults free of prevalent cardiovascular disease, there was an 
independent association between CAC and electrocardiogram diagnosed ischemia as induced by 
exercise treadmill testing but not with the duration of exercise on treadmill testing. 
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3.2 INTRODUCTION 
 Electron Beam computed tomography (EBT) is a noninvasive technique for the detection and 
quantification of coronary artery calcification (CAC), a reflection of the total atherosclerotic 
burden.  While in younger aged adults there have been studies reporting on the association 
between CAC and various measures of its physiologic significance, including exercise testing1, 2 
and the stress single photon emission computed tomography (SPECT)3-7,  there is limited data on 
the physiologic significance of CAC as measured by treadmill exercise testing in community-
dwelling elderly without prevalent cardiovascular disease. 
Conventional classification system recognizes CAC scores of 100-399 and  ≥ 400 as  
moderate and severe atherosclerosis, respectively8.  Previous investigations of the association 
between CAC and stress induced myocardial ischemia utilizing perfusion imaging have 
suggested the presence of a CAC threshold with a greater than a two-fold increase in the 
frequency of stress induced ischemia when CAC ≥ 400 are compared to CAC of 100-3993,4.  In 
older adults, a significant proportion exceed this threshold of CAC, with 59% of older men and 
36% of older women having CAC ≥ 4009.  While the age-related increase in the prevalence and 
extent of CAC has been recognized, the relationship between the extent of CAC and stress 
testing physiologic and ischemic parameters in community-dwelling older adults is unknown.   
Given the additional utility of the exercise treadmill testing in providing valuable insight 
regarding functional capacity beyond electrocardiographic ischemic changes10,11, we investigated 
the relationship of CAC, as measured by EBT scan, with exercise duration on treadmill testing 
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and also with exercise-induced ischemia, as detected by an electrocardiogram, in a cohort of 
community-dwelling older adults without prevalent cardiovascular disease.   
3.3 METHODS 
3.3.1 Population 
The Cardiovascular Health Study (CHS) and  Arterial Calcification in the Elderly in 
Cardiovascular Health Study (ACE-CHS) design and methods have been previously described 
elsewhere9,12,13.  Between 2001 and 2003,  131 participants from the CHS Pittsburgh field center 
who were free of clinical cardiovascular disease at time of assessment underwent both an EBT 
and exercise treadmill testing.  
Participants from the original ACE-CHS cohort (1998-2000) without cardiovascular 
disease, including a myocardial infarction, angina, transient ischemic event, stroke, intermittent 
claudication, valve heart surgery, peripheral or cardiac revascularization, cardiac device 
implantation, and also participants with cognitive or physical mobility impairment were 
excluded.  Cardiovascular events were ascertained every 6 months either by phone contact or at 
the clinical examination, validated by medical record review, and adjudicated by committee14.  
Of the 614 original ACE CHS participants, 289(47%)  had CVD, 39(6%) had either a physical or 
cognitive limitation and/or no longer community-dwelling, 53(15%)  were unable to walk on 
treadmill (8.6%), 92 refused study participation, 5(1%)  died during study , 2(0.3%)  had interim 
medical illness after start of study, and 3(0.5%) were not able to have their CVD status 
confirmed or had scheduling conflicts. 
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3.3.2 Coronary Artery Calcification 
Coronary artery calcification was assessed using an Imatron C-150 EBT scanner and the 
Agatston scoring method15, as previously described9.   
3.3.3 Exercise Treadmill Test 
Participants performed a graded exercise test according to a modified Balke protocol in which 
the speed is held constant and the elevation raised in stages16.  Briefly, the initial stage of the 
treadmill test began with participants walking for 2 minutes at a speed 2.0 mph and 0% grade.  
After this initial stage, the speed was increased to 3.0 mph at 0% grade in women, and 3.5 mph 
in for the men and elevation raised 3% every two minutes, until exhaustion or stop parameters 
are reached while maintaining the same speed. Participants unable to keep pace during  Stage 1 
were excused. If the participant was able to keep pace at Stage 1 but unable to keep pace at Stage 
2, then the exercise testing using the Modified Balke protocol was substituted by a Modified-
Modified Balke protocol.  
The exercise was symptom-limited and was continued until one the following was 
reached:(1) the heart rate reaching the age-predicted maximum heart rate (220-age);(2) 
hypotensive response to exercise; (3) symptoms of moderate to severe angina; (4) volitional 
exhaustion; or, (5) a positive ECG concerning for exercise induced ischemia.  A positive test was 
defined as a horizontal ST depression greater or equal to 1 mm occurring 80 milliseconds after 
the J-point during exercise or recovery. The exercise test was supervised and interpreted by 
physicians at the University of Pittsburgh Medical Center.  
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3.3.4 Demographics and Other Confounders 
Age was assessed at time of the Electron Beam CT scan. The status of hypertension,  diabetes, 
chronic obstructive pulmonary disease, smoking, self-reported health and arthritis were assessed 
at the 2001 to 2002 examination.  Hypertension was defined by self-report of high blood 
pressure, diagnosis by a physician, or use of an antihypertensive medication. Diabetes was 
defined by self-report of diabetes or use of a diabetes-related medication.  Chronic Pulmonary 
disease was defined by self-report of emphysema or asthma diagnosed by a physician.   Arthritis 
was defined by a self-report of arthritis involving either the hips or knees.  Body mass index was 
expressed as kilograms per meters squared (kg/m2).   Smoking status was reported as ever versus 
never because there were few current smokers.  Gait speed was calculated from duration of time 
in seconds to walk a distance of 15-foot at the usual walking pace.  
3.3.5 Outcomes 
 The outcomes of interest were both the duration of exercise on treadmill testing and also the 
occurrence of exercise induced-ischemia as detected by the electrocardiogram, defined as 
horizontal or down-sloping ST segment depression >1mm.    
3.3.6 Statistical Analysis 
Analysis of Variance or Kruskal Wallis test determined the association between continuous 
variables and tertiles of exercise duration on treadmill testing.  Wilcoxon Rank Sum test or 
Student's t test determined the association between continuous variables and dichotomous 
   90 
covariates.  Chi Square test was used to assess the association between categorical variables.  
Exercise treadmill testing ECG findings which were negative or non-diagnostic for ischemia 
were coded as negative ECG for ischemia whereas ECG positive for ischemia were based on 
definition previously described. Logistic regression determined the covariates independently 
associated with study endpoints.  Statistical significance was defined as a two-tailed P<0.05.  All 
statistical analyses were performed using STATA 11.1 (STATA Corporation, College Station, 
TX). 
3.4 RESULTS 
The duration of exercise on the treadmill and CAC was measured in 131 predominantly female 
(60.31%) and of white race (74.81%) community-dwelling older adults without prevalent clinical 
CVD.  Table 3.1 displays the participant characteristics by gender.  Participant mean age was 
82.2 years and did not significantly different between men and women.  The men were taller, 
heavier in weight, and had a significantly better physical performance as assessed by the 6 MWT 
distance and gait speed. The differences in CAC ((median, 48.9; IQR, 248.4,854.0) vs. 
(median,19.9; IQR, 125.0,536.0), p=0.19) did not reach statistical significance.  Similarly, the 
proportion of participants with diabetes, hypertension, chronic pulmonary disease, arthritis, and a 
fair or poor general health status did not differ significantly between men and women.    
The distribution of CAC in the study participants is shown in FIGURE 3.1.  The median 
CAC score was 166.5(Inter-quartile range, 34.0,659.8) with a wide range from 0 to 4,209.97.  
Majority of the participants 122 (93.1%) had at least some quantity of CAC (CAC>0).  Table 3.2 
displays the characteristics of participants by tertile of CAC score.  Participants with the higher 
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CAC score were significantly older and more likely to be of white race.  The participant 
characteristics, including lifestyle, anthropometric variables, chronic health conditions, and 
physical performance measures did not differ significantly across tertile of CAC. 
The median(Inter-quartile range) duration of exercise on the treadmill was 4.0(2.3,6.4) 
and did not differ significantly between men and women(P=0.64). While the resting heart rate 
was higher in women than men (73.38±10.67 vs. 69.15±12.63, p= 0.03), differences between the 
other resting and peak exercise measures, including the resting systolic blood pressure 
(134.71±19.17 vs. 137.35±21.35, p=0.52), resting diastolic blood pressure(74.54±9.49 vs. 
76.5±9.31, p= 0.22),   peak systolic blood pressure (161.44±22.48 vs. 164.29±27.32, p=0.67), 
peak diastolic blood pressure(82.77±13.42 vs. 83.19±12.02, p= 0.97), and the peak heart 
rate(126.0±15.50 vs. 125.67±14.97, p= 0.77) did not differ significantly.  Overall, there were 
10(7.73%) participants with exercise-induced ischemia with a non-significant difference between 
women and men(5(6.33%) vs. 5(9.62%), p=0.52). 
Table 3.3 displays the characteristics of the participant characteristics by tertile of 
treadmill exercise time.  After adjusting for age and sex, the factors independently associated 
with a treadmill performance in the highest tertile of treadmill exercise time (>5 minutes) 
included a longer distance walked during 6 minutes and the absence of hypertension (TABLE 
3.4).    
Table 3.5 displays the relationship between coronary artery calcification and treadmill 
exercise test physiologic and electrocardiogram measures.  While the association between resting 
and peak exercise parameters were non-significant, there was a trend towards a higher proportion 
of positive exercise-induced ECG ischemic with a higher coronary artery calcification (P=0.06).  
Coronary artery calcification (CAC>0) was present in all (100%) participants with a exercise 
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induced ischemia as detected by an electrocardiogram.  The proportion of exercise 
electrocardiogram positive for ischemia by coronary artery calcification score according to a 
conventional categorization of  no atherosclerosis (CAC=0), minimal atherosclerosis(CAC,1-10), 
mild atherosclerosis(CAC,11-100), moderate atherosclerosis(CAC,101-400), and extensive 
atherosclerosis(>400) was 0%, 7.7%, 3.3%, 2.9%,15.6%, respectively.  In a multiple logistic 
model adjusting for the traditional risk factors, a coronary calcification score of ≥ 400 remained 
independently associated with a 8.86 (1.68-46.70) greater odds of an ischemic electrocardiogram 
response compared to a coronary artery calcification score <400 with exercise testing (TABLE 
3.6). 
3.5 DISCUSSION 
Our study describes the relationship between the extent of coronary artery calcification as 
detected by EBT and both the exercise duration and exercise-induced ischemia by 
electrocardiogram detection during treadmill testing in community-dwelling older adults without 
prevalent cardiovascular disease.  In agreement with prior studies of the relationship between 
coronary artery calcification and myocardial ischemia detected by either exercise testing1,18 or 
myocardial perfusion scanning3-5 in younger adults, our findings revealed an association between 
coronary artery calcification and an ischemic electrocardiogram stress testing response in a 
cohort of older adults without prevalent cardiovascular disease.  Similarly, our findings of a lack 
of significant relationship between exercise duration and the presence of coronary artery 
calcification is also consistent with previous reports19.  To the best of our knowledge, our study 
is the first to explore these relationships between the two noninvasive measures of coronary 
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artery disease in a cohort of community-dwelling older adults without prevalent cardiovascular 
disease. 
 The assessment of coronary artery calcification as a measure of the anatomic 
atherosclerotic disease and the exercise treadmill testing in the evaluation for the physiological 
significance of atherosclerotic disease serve as noninvasive measures for individuals at risk for 
coronary artery disease.  Previous studies investigating the relationship between exercise testing 
induced ischemia detected by an electrocardiogram and the presence of coronary artery 
calcification using fluoroscopic techniques have reported a higher proportion of positive exercise 
induced ST segment depression in persons with fluoroscopically detected coronary artery 
calcification. In a study by Langou et al,  the prevalence of positive exercise ST depression in 
asymptomatic middle-aged men with fluoroscopically detected coronary artery calcification was 
reported to be 35% compared to 4% in those without coronary artery calcification18.   In study by 
Alexopoulos et al, an ECG-positive for ischemia induced by an exercise test was detected in 29% 
of those with versus 8% of participants without flouroscopically detect coronary artery 
calcification1.  In contrast to these two reports, an investigation of the relationship between 
EBT detected coronary artery calcification and ischemia detected by an electrocardiogram 
during stress testing did not reveal a significant difference in abnormal electrocardiograms across 
increasing coronary artery calcification scores3.  However, in addition to the use of EBT to 
detect coronary artery calcification, the participants in this study were younger (mean age, 53 
years), predominantly male (69%), and underwent stress testing by several different methods  
(Bruce protocol treadmill (86%), adenosine (11%), dobutamine (3%)).  More recently, 
investigators have examined the relationship between the extent of coronary artery calcification 
as measured by EBT or multi-detector spiral computed tomography (MDCT)  and the 
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myocardial perfusion by single photon emission computed tomography(SPECT) have revealed a 
clear increase in the frequency of abnormal myocardial perfusion with increasing extent of 
coronary artery calcification.3-5,7.  He et al reported the rate of ischemia by myocardial perfusion 
imaging to increase from 0% in those with coronary artery calcification score of 0, 2.6% with 
CAC scores 11 to 100, 11.3% with CAC scores from 101 to 399, and 46% in those with CAC 
scores ≥ 4003.  Similarly, in a study by Moser et al the rate of ischemia by myocardial perfusion 
imaging to increase from 5% in those with coronary artery calcification score < 100, 24% with 
scores from 101 to 400, and 53% in those with scores > 4004.   
The exercise treadmill stress test is less sensitive than a myocardial perfusion modality in 
detection of the physiological significance of the extent of coronary artery calcification.  Despite 
this limitation, our findings revealed a similar relationship between the frequency of an exercise-
induced ischemia and a coronary calcification score >400.  Moreover, we found that a coronary 
artery calcification score >400 was associated with a greater than 8-fold increase in the odds of 
an exercise-induced ischemia as detected by an electrocardiogram relative to coronary artery 
calcification score <400.  
In our assessment of the relationship between the extent of coronary artery calcification 
and exercise duration on the treadmill, we had hypothesized that an increased burden of coronary 
artery calcification would lead to exercise-induced ischemia which would subsequently result in 
ventricular dysfunction which is associated with reduced exercise tolerance.  This hypothesis 
was supported by literature revealing an association between subclinical cardiovascular disease 
and reduced left ventricular function and impaired physical function20-24.  However, we did not  
find a significant relationship between coronary artery calcification and duration of exercise on 
the treadmill. Our results are consistent with previously published studies in both the young 
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adult23 and older aged adult populations.19  In a study of 3,163 participants (mean age, 59±8 
years)  of the Heinz Nixdorf Recall study, who were free of established coronary artery disease, 
the inverse associated observed in unadjusted analyses between EBT-detected coronary artery 
calcification score and the mean treadmill duration was no longer significant after adjusting for 
age and gender23.  Similarly, in a study of 38 asymptomatic men (mean±SD age, 59±8 years) 
enrolled in the South Bay Heart Watch Program who were without prior history of angina or 
myocardial infarction the presence of coronary artery calcification as detected by digital 
subtraction cardiac fluoroscopy was not associated with exercise tolerance19.  Several factors 
may account for the reduced exercise capacity in the elderly, including reductions in both 
skeletal muscle mass, capillarization, and mitochondrial enzyme activity25.  Diastolic 
dysfunction has also been shown to be inversely associated with reduced exercise capacity26 and 
could potentially serve as the mechanism by which individuals with hypertension had a nearly 
60% reduction in the odds of the ability to exercise a duration in the top tertile  of > 5 minutes.  
Finally, we found the distance walked during a six minute walk to be  independently associated 
with the odds of the ability to exercise duration in the top tertile of > 5 minutes, such that 
individuals who walked a distance of more than 337 meters  had a more than a three-fold greater 
odds than those walking shorter distances.  Therefore, the six minute walk distance may serve 
useful in the selection  elderly capable of treadmill testing as a trend for a longer distance walk 
was observed in treadmill capable older adults in our study cohort.  This observed relationship 
between the six minute walk distance and exercise treadmill duration in older adults highlights 
the need for further investigation. 
Several limitations  have to be acknowledged.  First, it has been previously recognized 
that treadmill testing in elderly does not replicate real life situations27 which may have resulted in 
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early termination of treadmill testing prior to achieving a peak exercise capacity. Accordingly, 
we selected to utilize a modified Balke treadmill protocol which is most-suited for elderly 
individuals with a wide range of exercise capacities and has been used in other epidemiologic 
cohorts including the Baltimore Longitudinal Study on Aging10.  Second, the cross-sectional 
design limits speculations regarding cause-effect relationship.  Third, possible selection bias due 
to differences between participants with and without an EBT scan and/or a clinic visit for 
physical function assessment.  Finally, more than one-half of study participants treadmill test 
were terminated due to lower extremity symptoms, such as fatigue, pain, or cramps, which may 
indicate non-cardiopulmonary may have been a limiting factor to reaching a sufficient exertion 
threshold to detect ischemia on the electrocardiogram. 
In this study of community-dwelling older adults free of clinical cardiovascular disease at 
the time of EBT and treadmill testing, we demonstrated that subclinical coronary artery disease 
as measured by coronary artery calcification was associated with physiologically significant 
ischemia  but not exercise duration with treadmill testing.  The presence of hypertension was also 
inversely associated with reduced exercise capacity.  These findings highlight the potential for 
cardiovascular risk factor modification in maintaining functional capacity which likely not only 
reflects physical fitness but overall the overall health status.  Preventative therapies targeting 
cardiovascular risk factors, including lipids and blood pressure, may have a significant beneficial  
role extending into the oldest ages in maintaining health and thereby functional capacity. 
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3.7 TABLES FOR CHAPTER 3 
 









CAC score 166.5(34.0,659.8) 48.9(248.4,854.0) 19.9(125.0,536.0) 0.19 
Age, y 82.2±3.2 82.2±3.2 82.2±3.2 0.97 
Non-white Race 33(25.2) 13(25.0) 20(25.3) 0.97 
BMI,  kg/m2 26.2(3.9) 25.61(3.7) 26.62(4.0) 0.15 
Height, m 1.6±0.10 1.7±0.1 1.6±0.1 <0.01 
Weight, kg 71.0±12.9 77.4±12.9 66.7±11.0 <0.01 
Smoking  69(53.1) 30(57.7) 39(50.0) 0.39 
Fair or Poor Health  37(28.2) 13(25.0) 24(30.4) 0.50 
6 MWT distance, m 366.2±63.2 389.8±64.4 350.6±57.7 <0.01 
Gait Speed, m/sec  0.80±0.18 0.86±0.18 0.76±0.16 <0.01 
Hypertension  67(51.2) 25(48.1) 42(53.2) 0.57 
Diabetes Mellitus  19(14.5) 10(19.2) 9(11.4) 0.21 
Pulmonary Disease  11(8.4) 2(3.9) 9(11.4) 0.20 
Arthritis  32(24.4) 12(23.1) 20(25.3) 0.77 
Abbreviations:  CAC refers to coronary artery calcification Agatston score; IQR, interquartile range; y, 
years; SD, standard deviation; n, number, %, percent; BMI, body mass index; kg, kilogram; Smoking, 
current or former smoker; m, meters. 
*Characteristic presented as n(%), mean±sd, or median(IQR). 
 
















Age, y  82.2±3.2 81.2±3.3 82.2±3.2 83.0±2.9 0.03 
White Race  98(74.8) 22(50.0) 36(81.8) 40(93.0) <0.01 
Male  52(39.7) 14(31.8) 18(40.9) 20(46.5) 0.37 
BMI,  kg/m2 26.5±3.8 27.5±4.1 25.9±3.7 26.0±3.4 0.08 
Height, m 1.6±0.1 1.6±0.1 1.7±0.1 1.7±0.1 0.50 
Weight, kg  71.0±12.9 71.9±12.6 70.9±12.2 70.1±14.1 0.81 
Smoking  69(53.1) 20(45.5) 28(65.1) 21(48.8) 0.15 
6 MWT distance, m  366.2±63.2 368.2±61.6 359.3±71.9 371.1±55.9 0.66 
Gait Speed, m/s  0.8±0.2 0.8±0.1 0.8±0.2 0.8±0.2 0.71 
Hypertension  67(51.2) 24(54.6) 22(50.0) 21(48.8) 0.85 
Diabetes Mellitus  19(14.5) 6(13.6) 7(15.9) 6(13.9) 0.95 
Pulmonary Disease  11(8.4) 4(8.9) 2(4.7) 5(11.6) 0.54 
Arthritis  32(24.4) 9(20.5) 13(29.6) 10(23.3) 0.60 
Fair or Poor Health  37(28.2) 14(31.1) 10(23.3) 13(30.2) 0.67 
Abbreviations:  Treadmill capability refers to the ability to complete both the warm up and first 
stages of treadmill protocol; T, tertile;6 MWT, 6 Minute Walk Test; n, number; y, year; SD, 
standard deviation; n, number; waist size, waist circumference; %, percent; kg, kilograms; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; m, meters; sec, seconds; CAC score, 
coronary artery calcification. 
*Characteristic presented as n(%), mean±sd, or median(IQR). 
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Table 3.3 Participant characteristics by tertile of treadmill exercise duration(min) 
(range in parentheses)  
Characteristics* 
T1                        
(0.35- 2.7) 
T2 
    (2.75-5.05) 
T3        
(5.17- 14) P Value 
CAC score 256.4(47.0,700.6)  131.8(38.1,765.5)  254.4(14.0,613.0)  0.78  
Age, y 82.7±3.6  82.0±2.6 81.8±3.3 0.34 
White Race  30(66.7) 34(79.1) 34(79.1) 0.30 
Female  30(66.7) 23(53.5) 26(60.5) 0.45 
Height, m  1.6±0.1 1.7±0.1 1.7±0.1 0.50 
Weight, kg  71.9±12.6 71.0±12.2 70.1±14.1 0.81 
BMI, kg/m2  27.6±4.1 26.2±3.8 25.7±3.3 0.05 
Smoking  20(44.4) 25(58.1) 21(48.8) 0.43 
Resting SBP, mm Hg  134.0±19.9 139.5±21.1 133.9±19.1 0.40 
Resting DBP, mm Hg 74.5±9.6 76.3±9.7 75.2±9.1 0.74 
Resting HR,beats/min 72.4±10.8 72.4±12.6 70.3±11.6 0.63 
6 MWT distance, m  350.2±66.2 360.1±61.7 389.0±56.0 0.01 
Gait Speed, m/s  0.7±0.2 0.8±0.2 0.9±0.2 0.01 
Hypertension  28(62.2) 24(55.8) 15(34.9) 0.03 
Diabetes Mellitus  8(17.8) 5(11.6) 6(14.0) 0.75 
Pulmonary Disease  6(13.3) 4(9.3) 6(14.0) 0.84 
Arthritis  15(33.3) 11(25.6) 6(14.0) 0.10 
Abbreviations:  T refers to tertile; 6 MWT, 6 Minute Walk Test; n, number; y, 
year; SD, standard deviation; n, number; waist size, waist circumference; %, 
percent; kg, kilograms; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; m, meters; sec, seconds; CAC score, coronary artery calcification 
Agatston score. 
*Characteristic presented as n(%), mean±sd, or median(IQR). 
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Table 3.4 Multiple logistic model: Characteristics association with treadmill exercise 













Characteristics OR (95% CI) P Value 
Age,  per 5 y 0.75 (0.38,1.49) 0.41 
Male 0.72 (0.32,1.64) 0.43 
6 MWT  distance(meters)  0.02 
240 - 336 1.00  
337- 389 3.09 (1.07,8.83)  
390 -561 4.47 (1.54,12.96)  
Hypertension 0.42 (0.19-0.92) 0.03 
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(>423)  P Value 
Treadmill Time, min 4.0(2.3,6.4) 4.1(2.3,7.3) 4.1(2.3,5.2) 3.1(2.3,5.9) 0.54 
Resting SBP, mm Hg 135.8±20.0 138.4±22.0 134.4±19.2 134.4±18.9 0.57 
Resting DBP, mm Hg 75.3±9.4 76.0±9.8 75.2±10.4 74.8±8.2 0.83 
Resting HR, beats/min 71.7±11.6 72.5±13.4 72.4±11.6 70.1±9.5 0.55 
Peak SBP, mm Hg 162.6±24.5 165.9±26.7 157.6±22.6 164.3±23.6 0.25 
Peak DBP, mm Hg 82.9±12.8 83.6±17.8 82.2±9.7 83.0±9.5 0.31 
Peak HR, beats/min 125.9±15.2 127.6±16.0 125.3±13.2 124.7±16.6 0.64 
ECG ischemia 10(7.7) 2(4.6) 1(2.3) 7(16.3) 0.06 
Abbreviations:  T refers to tertile; 6 MWT, 6 Minute Walk Test; n, number; y, year; sd, standard 
deviation; n, number; waist size, waist circumference; %, percent; kg, kilograms; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; m, meters; sec, seconds; CAC score, coronary artery 
calcification Agatston score. 
* Characteristic displayed as n(%), mean±SD, or median(Inter-quartile range).  
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Table 3.6 Simple and Multiple logistic Models: Association of 






















OR  (95% CI) 
CAC score    
     <400 1.00 1.00 
     ≥400 5.30(1.30-21.63) 8.86(1.68-46.70)  
Age, per 5 years 0.49(0.16-1.54)  0.35(0.08-1.53) 
Male gender 1.57(0.43-5.73) 1.23(0.27-5.52) 
BMI      
     <30 1.00 1.00 
     ≥30 1.19(0.24-6.01) 1.67(0.26-10.67) 
Smoking 1.36(0.36-5.05) 0.82(0.18-3.68) 
Hypertension 0.61(0.16-2.28) 0.39(0.08-1.84)  
Diabetes Mellitus 4.71(1.19-18.65) 4.80(0.90-25.47)  
Abbreviations: OR represents odds ration; CAC, coronary artery 
calcification Agatston score; BMI, body mass index. 
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Figure 3.1  Distribution of Coronary Artery Calcification among Study Participants 
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4.1 ABSTRACT 
Background:  The conventional method to assess functional exercise capacity is by the treadmill 
exercise test yet the 6 Minute Walk test (6 MWT) has several distinct advantages especially in 
the community-dwelling older adult.  Aim:  To determine the utility of the 6 MWT in identifying 
community-dwelling elderly with the capability of an evaluation with treadmill testing.  
Additionally, we  investigated the association between the 6 MWT distance and a functional 
capacity ≥4 Metabolic Equivalents (METs) as assessed by the treadmill exercise test.  Methods:  
Participants of the Arterial Calcification in the Elderly (ACE) in Cardiovascular Health Study 
(CHS) without cardiovascular disease were evaluated for participation in a physical function and 
exercise testing follow-up study.  A total of 205 participants had a clinic visit including a 
functional exercise capacity assessment with the 6 MWT and an exercise treadmill test according 
to a modified Balke protocol.  Among the 205 participants with a clinic based assessment, 183 
completed, 6 partially completed, and 16 did not have a 6 MWT.  Of the 189 participants with a 
6 MWT, there were 142 who were able, 35 unable, and 12 refusing the treadmill exercise test. 
Results:  The mean age of the participants with treadmill testing was 80.8 years (female, 58%). 
The mean 6 MWT distance was 366.62±61.94 in tested, 351.08±76.41 refused, and 
262.55±90.02 in participants who refused the treadmill exercise test(p=0.0001).  In a fully 
adjusted model there was a nearly 3-fold increase in the odds of a participant being treadmill test 
capable per 100 meter increase in the 6 MWT distance (OR, 3.84 [95% CI, 1.95 to 7.60]). Of the 
142 participants with a treadmill test, a total of 62 (44%) had a treadmill  functional performance 
with an estimated MET ≥ 4.  The mean 6 MWT distance was significantly greater in participants 
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with MET≥ 4 as compared to those with MET <4 (383.82±53.58 vs. 353.30±64.96, p=0.003).  
After adjusting for demographics, lifestyle, and health conditions there was a nearly 2-fold 
increase in the odds of achieving an estimated MET ≥ 4 per 100 meter increase in 6 MWT 
distance (OR, 2.03 [95% CI, 1.02 to 4.03]).  Walk distance of ≥ 407 meters in 6 minutes was 
90.2% specific for treadmill testing capability and a 6 MWT distance ≥416 meters was 83.8% 
specificity for having a functional capacity of ≥ 4 MET.  Conclusion:  The 6 MWT is a quick 
and simple test useful in the selection of community-dwelling older adults capable of a 
conventional treadmill exercise test in addition to providing an estimate of functional exercise 
capacity. 
   110 
4.2 INTRODUCTION 
Exercise capacity is an independent predictor of all-cause and cardiovascular disease related 
mortality in both middle-aged and older adults1-9.  In addition, a higher level of functional 
capacity has been shown to be associated with reduced healthcare costs10.  Moreover, fitness is 
essential for the ability to perform daily activities with a low functional capacity serving as a 
predictor of disability and making independent community dwelling difficult11-13.  Therefore, the 
significance of assessing functional capacity rests on its predictive ability in determining the 
onset of disability, health resource utilization, and adverse health outcomes.  
The assessment of functional capacity in the elderly is challenging since older aged adults 
frequently encounter difficulties in performing a treadmill-based fitness assessment14.  While the 
exercise treadmill test serves as the conventional method and gold standard for the assessment of 
functional capacity, the 6 Minute Walk test ( 6 MWT) represents an alternative that has been 
utilized in diverse disease-specific populations.  The 6 MWT,  a correlate of cardiorespiratory 
fitness, can be safely performed by most community-dwelling older adults15.  The 6 MWT has 
several advantages over the conventional exercise treadmill test, including safety and lower cost. 
We aimed to determine the utility of the 6 MWT in the identification of treadmill test capable 
older adults.  Additionally, we assessed the association between 6 MWT distance and functional 
exercise capacity on treadmill testing.  More specifically, we investigated the association 
between the distance walked in 6 minutes and having a functional capacity ≥4 Metabolic 
Equivalents (METs) on a treadmill-based testing in a cohort of community-dwelling older adults 
without cardiovascular disease. 
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4.3 METHODS 
4.3.1 Population 
The Cardiovascular Health Study (CHS) and the Arterial Calcification in the Elderly in 
Cardiovascular Health Study (ACE-CHS) study design and methods have been previously 
described elsewhere16-18.  Participants from the ACE-CHS study free of prevalent cardiovascular 
disease were evaluated for their eligibility to participate in a clinic based physical function and 
exercise testing follow-up study. 
A total of 289 participants from the original ACE-CHS cohort (n=614) had interim 
cardiovascular disease during annual and semi-annual surveillance.   A cardiovascular disease 
event was defined as an incident myocardial infarction, angina, transient ischemic event or 
stroke, intermittent claudication, and any cardiovascular-related procedures, including coronary 
artery bypass graft, valve heart surgery, cardiac catheterization, implanted pacemaker or 
defibrillator, carotid endarterectomy, and peripheral vascular angioplasty or other vascular 
lower-extremity surgery.  Among those remaining who were excluded from study participation, 
there 39 persons who did not participate due to nursing home residence, presence of cognitive 
impairment, or a self-report of inability to walk.  Lastly, two participants were excluded due to 
reasons related to geographic relocation and unknown CVD status. 
 Based on the exclusion process 284 remained eligible for the study, however, 205 had a 
clinic-based study visit.  The remaining 79 participants were either agreeable only to a telephone 
interview (n=60), refused both a clinic visit and a telephone interview (n=18), or had a 
scheduling conflict preventing a clinic visit(n=1). There were 16 individuals excluded from the 
six minute walk test (6 MWT) due to use of an ambulatory aid (wheelchair, crutches, walker or 
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cane), heart rate (HR) abnormalities (HR<50 or HR>110), severe aortic stenosis, elevated blood 
pressure (systolic blood pressure>200 or diastolic blood pressure>110), and/or new or worsening 
symptoms of chest pain, shortness of breath or fainting during the previous 2 months.    Among 
the 205 participants with a clinic visit, 189 individuals remained eligible for a 6 MWT.   
4.3.2 Six Minute Walk Test  
The 6 MWT was conducted according to a standard protocol similar to the American Thoracic 
Society guidelines19.  Briefly, in a 100 foot section of an internal hallway with distance marked 
every five feet by colored tape along the baseboard, participants were instructed to "walk at their 
own pace" up and down the hallway while attempting to cover as much ground as possible.  This 
was the only difference between the CHS protocol for the 6 MWT and the American Thoracic 
Society guidelines where 6 MWT participants are encouraged to "cover as much distance as 
possible in 6 minutes".  Technicians encouraged the participants with the standardized statements 
"You are doing well" or "keep up the good work," but were asked not to use other phrases.  
Participants were allowed to stop and rest during the test, but were instructed to resume walking 
as soon as they could.  If a participant stopped and refused to continue the test before the six 
minutes were up, the distance was recorded and the walk coded as a partial test.  The technician 
used a mechanical lap counter to count the number of laps completed, and an electronic timer 
with a buzzer that sounded the completion of the 6 minutes.  While oxygen saturation and pulse 
rate were recorded prior to the exercise, the technicians did not walk with participants and did 
not observe the pulse oximetry readings during the exercise. 
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4.3.3 Exercise Treadmill Test 
Participants performed a graded exercise test according to a modified Balke protocol in which 
the speed is held constant and the elevation raised in stages20.  Briefly, the initial stage of the 
treadmill test began with participants walking for 2 minutes at 2.0 mph and 0% grade.  After this 
initial stage, the speed was increased to 3.0 mph at 0% grade in women, and 3.5 mph in for the 
men and elevation raised 3% every two minutes, until exhaustion or stop parameters are reached, 
maintaining the same speed. Participants unable to keep pace during  Stage 1 were excused. If 
the participant was able to keep pace at Stage 1, but unable to keep pace at Stage 2, the exercise 
testing using the Modified Balke protocol was substituted by a Modified-Modified Balke 
protocol where the grade remained constant. The estimated of exercise intensity  was measured 
in metabolic equivalents (METs) and was calculated using the American College of Sports 
Medicine(ACSM) walking equation21.  The ACSM's walking equation defines METs  as the rate 
of oxygen consumption(VO2) divided by 3.5. (VO2 was equivalent to 0.1*Speed(meter minute -
1) +1.8*Speed(meter minute-1)*Grade(%)+3.5).  
The exercise were symptom-limited and were continued until one the following was 
reached:(1) the heart rate reaching the age-predicted maximum heart rate (220-age);(2) 
hypotensive response to exercise; (3) symptoms of moderate to severe angina; (4) volitional 
exhaustion; or, (5) a positive ECG concerning for exercise induced ischemia.  A positive test was 
defined as a horizontal ST depression greater or equal to 1 mm occurring 80 milliseconds after 
the J-point during exercise or recovery. The exercise test was supervised and interpreted by 
physicians at the University of Pittsburgh Medical Center.  
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4.3.4 Other Covariates 
Participant age was assessed at time of the clinic visit for the 6 MWT. The presence of 
hypertension,  diabetes, chronic pulmonary disease, arthritis were assessed at the time of the 
most recent CHS annual examination.  Hypertension was defined by self-report of high blood 
pressure as diagnosed by a physician or use of an antihypertensive medication. Diabetes was 
defined by self-report of diabetes or use of a diabetes-related medication.  Chronic Pulmonary 
disease was define by self-report of emphysema, chronic bronchitis, or asthma as diagnosed by a 
physician.  Arthritis was defined by a self-report of arthritis involving the hips or knees.  
Anthropometric measures included weight (kilograms), height (meters), and waist 
circumference (centimeters).   Gait speed (meters per second) was calculated from the number of 
seconds to walk 15-feet at usual pace.   The primary endpoint for the treadmill exercise test was 
the estimated  Metabolic Equivalents (METs). 
4.3.5 Statistical Analysis 
Categorical and continuous variables were analyzed using Chi Squared test and t test or 
Wilcoxon Rank Sum test, respectively.  Analysis of Variance or the Kruskal Wallis test assessed 
for the significance of difference in continuous variables across 6 MWT status and treadmill test 
capability categories.  Simple and multivariable logistic regression provided an estimate of 
association between 6 MWT distance and a dichotomized outcome based on the participant 
capability of perform a treadmill exercise test (capable=1/not capable=0).   Similarly, logistic 
regression provided an estimate of the association between 6 MWT distance and a dichotomized 
outcome based on exercise treadmill-based functional capacity where a good functional capacity 
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was defined as an estimated MET ≥ 4.  All statistical analyses were performed using STATA 
11.1 (STATA Corporation, College Station, TX).   
4.4 RESULTS 
Participant characteristics by whether they completed, partially completed, or did not have a 6 
Minute Walk Test is shown in Table 4.1.  Among the 205 participants with a clinic based
assessment, 183 did complete and six persons partially completed a 6 MWT. Participants 
who completed the 6 MWT were younger and with a faster gait speed.  The characteristics of 
participants with a 6 MWT by whether or not they were capable of an exercise treadmill test is 
displayed in Table 4.2.  Of the 189 with a 6 MWT, there were 142 participants  who were also 
capable of performing the exercise treadmill test, while the others were either unable(n=35) or 
refused(n=12) the treadmill test. Compared with participants unable or refusing the testing,
treadmill test capable participants were younger, and taller in height.  The treadmill test capable 
had a longer 6 MWT distance and a faster gait speed compared to those unable to do a 6 MWT.
The association between the participants treadmill exercise testing capability and the 6 
MWT distance based on logistic regression modeling are displayed in Table 4.3.  In an 
unadjusted logistic model, a 100 meters increase in the 6 MWT distance was associated with an 
approximately 4-fold increase in the odds of a participant being treadmill test capable (OR, 4.18 
[95% CI, 2.34 , 7.47]).  The independent association between the 6 MWT distance and 
treadmill exercise testing capability remained statistically significant in an age- and sex-adjusted 
model with a 3-fold increased odds per 100 meter increase in 6 MWT distance (OR, 3.80 [95% 
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CI, 2.07 , 7.00]). After further adjusting for lifestyle and clinical factors there remained a 
greater than 3-fold increase in the odds of a participant being able to be treadmill tested per 100 
meter increase in 6 MWT distance (OR, 3.84 [95% CI, 1.95 , 7.60]).  The changes in the 
sensitivity, specificity, and likelihood ratio associated with several cut-offs in 6 MWT distance in 
the association with treadmill testing capability is displayed in TABLE 4.4.   As illustrated in 
Table 4.4, the sensitivity of the 6 MWT decreases with longer distances walked ranging from 
100% for 152.4 to 287.4 meters to 0% for 6 MWT distances greater than 560.2 meters.  A 
distance of 407.8 to 560 meters in 6 minutes was low in sensitivity (31%), but walking this 
distance increased the likelihood of being capable of treadmill testing (positive LR, 2.31). 
Table 4.5 displays the characteristics of the 142 participants who underwent an exercise 
treadmill test by functional exercise capacity.  The mean age of the participants with treadmill 
testing was 80.8 years (female, 58%). Of the 142 participants, a total of 62 (44%) had a treadmill  
functional performance with an estimated MET ≥ 4.  In comparison with those with poor 
functional performance (MET <4), individuals with a good treadmill performance (MET ≥ 4) did 
not differ significantly with respect to age, gender, and measures of height and waist 
circumference.    The mean diastolic blood pressure was significantly lower in participants  with 
estimated MET ≥ 4 ( 69.95±8.98 vs. 74.00±9.71, p=0.01) who were also less likely to carry a 
diagnosis of hypertension. 
Among participants with treadmill-based estimated MET ≥ 4, the mean distance walked 
on the 6 MWT was significantly greater as compared to individuals with MET <4 (383.82±53.58 
vs. 353.30±64.96, p=0.003).  Table 4.6 displays the results of the simple and multiple logistic 
regression models assessing the association between the 6 MWT distance and an estimated MET 
≥ 4 treadmill exercise capacity.  An increase of 100 meters in the 6 MWT distance was 
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associated with an approximately 2-fold increase in the odds of a participant having a functional 
capacity equivalent to an estimated MET ≥ 4  (OR, 2.32 [95% CI, 1.30 , 4.16]).  The 
independent association between the 6 MWT distance and treadmill exercise-based functional 
capacity equivalent to an estimated MET ≥ 4  remained statistically significant in an age- and 
sex-adjusted model with a 2-fold increased odds per 100 meter increase in 6 MWT distance (OR, 
2.24 [95% CI, 1.22 , 4.11]). After further adjusting for lifestyle and clinical factors there 
remained a greater than 2-fold increase in the odds of a participant achieving an estimated MET 
≥ 4 per 100 meter increase in 6 MWT distance (OR, 2.03 [95% CI, 1.02 , 4.03]).  The changes 
in the sensitivity, specificity, and likelihood ratio associated with several cut-offs in 6 MWT 
distance in the association with a participant achieving an estimated MET ≥ 4 on treadmill 
testing is displayed in TABLE 4.7.   The specificity of the 6 MWT increased with 6 MWT 
distance, ranging from 0% for 240.8 to 314.6 meters to 100% for 6 MWT distances greater than 
560.2 meters.  For example, among the 142 participants who had a treadmill exercise test and 
also completed a 6 MWT, those having walked at least 416 meters during six minutes had 83.8% 
specificity for having a functional capacity of ≥ 4 MET.    
4.5 DISCUSSION 
 In a cohort of community-dwelling older adults free of cardiovascular disease, the distance 
walked during a 6 minute was shown to be an independent predictor of treadmill exercise test 
capability.  Additionally, the 6 MWT distance was a useful indicator of whether an older adult 
would have a good functional capacity as determined by a conventional treadmill based 
assessment.  Based on our results, a distance ≥ 407 meters walked during 6 minutes has 90% 
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specificity in identifying whether a community-dwelling older adult would be capable of 
treadmill-based testing.  Additionally, using a definition of good functional capacity as ≥ 4 MET, 
we found that a distance ≥ 416.7 meters walked during the 6 MWT was moderately specific 
(83.4%) for a good functional capacity.  To the best of our knowledge, the application of 6 MWT 
distance as a tool to identify treadmill test capability and functional performance status of 
community-dwelling older adults without cardiovascular disease had not previously been 
reported. 
 In contrast to walking test, many elderly either do not meet eligibility criteria or are 
unwilling to participate in treadmill exercise testing14.  Previous study of treadmill testing in the 
elderly found an age-related decline in the ability to complete a treadmill test such that by age 85 
or older fewer than 10% were able to successfully complete the test22.  Therefore, walk-based 
tests can serve as an alternative or as the initial test to determine whether an older aged adult may 
be capable of performing a treadmill based assessment.   
We found the 6 MWT distance independently associated with treadmill test capability.   
For example, an individual able to walk at least 407.8 meters in 6 minutes would be very likely 
to be treadmill test capable (specificity, 90.2%).  In contrast, an individual unable to walk at least 
289.6 meters would be unlikely to be capable of undergoing a treadmill exercise testing.    
The 6 MWT distance can also serve as a simple tool in the identification of community-
dwelling older adults with a good functional capacity (MET≥4 ).  In this aim, we provided the 
diagnostic characteristics of the 6 MWT distance over a range of thresholds for the determination 
of treadmill testing treadmill testing performance ≥4 MET.  This relationship can serve an 
important role in the appropriate context in clinical care of the older adult.  For instance, an 
individual's functional capacity plays a role in pre-operative cardiovascular risk assessment 
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where a functional capacity < 4 METs may call a need for further cardiovascular testing.  While 
a survey of an individual's self-reported ability to participate in various physical activities can 
provide an estimate of the functional capacity, a formal test can provide an objective measure.  
Based on our results, objective assessment can be provided by the 6 MWT such that the inability 
to walk at least 320 meters in 6 minutes would identify older adults unlikely to be have a 
functional capacity ≥4 MET.   
 Several limitations of our results are noteworthy.  First, the possibility of verification or 
workup bias needs to be considered as study participants who were unable to complete the 6 
MWT were not referred for treadmill based testing.  Second, the estimation of VO2 is less 
accurate and reproducible than direct measurement of VO2.  Given the correlation between VO2 
and walk-based testing is greatest in older adults and those less-fit, our findings in community-
dwelling elderly may not be generalizable to other populations. 
The traditional method for assessing functional capacity is via the exercise treadmill test.  
Although the treadmill exercise test is considered the "gold standard", it has several limitations, 
including the requirement for oversight by clinically trained personnel, equipment costs, and 
safety concerns.  Additionally, the treadmill exercise testing has been reported to be impractical 
in the assessment of fitness in older adults23.  Alternatively, the 6 MWT is a valid and reliable 
method of physical endurance assessment which can be performed by many older adults unable 
to perform a conventional treadmill exercise test15,24.  Our findings, suggest that 6 MWT distance 
may serve as a useful tool in either the selection of elderly capable of the conventional treadmill 
exercise test and to provide an estimate of functional capacity for community-dwelling older 
adults.     
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4.7 TABLES FOR CHAPTER 4 
 












Age, y 83.5±3.5 83.0±4.5 81.2±3.4 0.02 
Female 10(62.5) 5(83.3) 114(62.3) 0.01 
Height, m 1.6±0.1 1.58±0.1 1.64±0.1 0.35 
Waist Size ,cm 1.0±0.14 1.0±0.2 1.0±0.1 0.82 
Weight, kg 70.3±13.5 69.9±18.7 71.2±13.6 0.94 
SBP, mm Hg 139.2±18.3 123.3±11.1 134.1±17.6 0.17 
DBP, mm Hg 72.7±11.5 72.5±9.7 72.0±9.9 0.97 
Walking Performance Tests 
  6 MWT, m NA 197.77±111.6 351.2±73.6 <0.01 
  Gait Speed, m/sec 0.6±0.2 0.7±0.2 0.8±0.2 0.01 
Prevalent Health Conditions 
Hypertension 15(51.7) 5(41.7) 65(45.8) 0.79 
Diabetes Mellitus 2(6.9) 4(33.3) 20(14.1) 0.09 
Pulmonary Disease 4(13.8) 3(25.0) 16(11.3) 0.32 
Arthritis 11(40.7) 4(36.4) 33(23.4) 0.15 
* Presented as mean ± SD or n(%). 
Abbreviations: 6 MWT represents 6 Minute Walk Test; SD, standard deviation; NA, not applicable; 
n, number; y, year; cm, centimeters; n, number; waist size, waist circumference; %, percent; kg, 
kilograms; SBP, systolic blood pressure; DBP, diastolic blood pressure; m, meters; sec, seconds. 
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Table 4.2 Characteristics of Participants with Completed 6 MWT by Treadmill Test 
Capability 







Age, y 82.4±3.5 82.7±4.6 80.9±3.2 0.02 
Female 30(85.7) 6(50.0) 83(58.5) 0.01 
Height, m 1.6±0.1 1.6±0.1 1.7±0.1 0.05 
Waist Size, m 1.0±0.16 1.0±0.1 1.0±0.1 0.60 
Weight, kg 69.9±16.8 74.4±10.0 71.3±13.1 0.63 
SBP, mm Hg 134.6±20.2 130.8±20.2 133.8±17.2 0.81 
DBP, mm Hg 71.9±11.5 70.0±9.7 72.2±9.6 0.76 
Walking Test Performance 
     6 MWT, m  262.6±90.0 351.1±76.4 366.6±61.9 <0.01 
     Gait Speed, m/sec  0.7±0.1 0.8±0.2 0.8±0.2 <0.01 
Prevalent Health Conditions 
Hypertension 19(54.3) 5(41.7) 65(45.8) 0.62 
Diabetes Mellitus 4(11.4) 4(33.3) 20(14.1) 0.18 
Pulmonary Disease 6(17.1) 3(25.0) 16 (11.3) 0.22 
Arthritis 13(39.4) 4(36.4) 33(23.4) 0.15 
* Presented as mean ± SD or n(%). 
Abbreviations: 6 MWT represents 6 Minute Walk Test; n, number; y,year; SD, standard 
deviation; n, number; %, percent; kg, kilograms; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; m, meters; sec, seconds. 
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Table 4.3 Association between Six Minute Walk Test Performance and Treadmill Test Capability 
 Logistic Models 
Characteristics Unadjusted 
Age- and Sex- 
Adjusted 
Fully Adjusted 

















Height, per 1 cm   
1.00 
(0.94,1.07) 
Waist circumference, per 1 cm   
1.01 
(0.97,1.05) 
SBP, per 5 mm Hg   
1.03 
(0.88,1.20) 
DBP, per 5 mm Hg   
0.97 
(0.74,1.26) 
Hypertension   
0.82 
(0.33,2.05) 
Diabetes Mellitus   
1.03 
(0.29,3.60) 
Pulmonary Disease   
1.00 
(0.29,3.34) 
Arthritis   
0.67 
(0.27,1.67) 
Abbreviations: 6 MWT represents 6 Minute Walk test; cm, centimeter; y, year; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; m, meters; sec, seconds. 
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Table 4.4 Association between 6 MWT Distance and Treadmill Test Capability 
6 MWT Distance (m) Sensitivity(%) Specificity(%) 
Correctly 
Classified (%) LR + LR - 
152.40 - 287.43 100 0 77.60 1.00  
289.56 - 338.03 88.73 51.22 80.33 1.82 0.22 
338.33 - 376.74 65.49 60.98 64.48 1.68 0.57 
377.35 - 406.30 44.37 75.61 51.37 1.82 0.74 
407.83 - 560.23 22.54 90.24 37.70 2.31 0.86 
560.23 0 100 22.40  1.00 
Abbreviations: 6 MWT refers to Six Minute Walk Test; m, meters; %, percent; LR +, Likelihood Ratio 
Positive; LR -, Likelihood Ratio Negative. 
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Table 4.5 Association between 6 MWT Distance and Treadmill Test Capacity 
 
 
* Presented as mean ± SD or n(%). 
Abbreviations: 6 MWT represents 6 Minute Walk Test; n, number; y,year; SD, standard deviation; n, 
number; %, percent; kg, kilograms; SBP, systolic blood pressure; DBP, diastolic blood pressure; m, 
meters; sec, seconds. 
 
 




<4                  
(n=80) 
≥4                   
(n=62) 
P Value 
Age, yr 80.5±2.9 81.2±3.5 80.5±2.9 0.20 
Female 83(58.5) 49(61.3) 34(54.8) 0.44 
Height, m 1.7±0.1 1.6±0.1 1.7±0.1 0.28 
Waist circumference, m 1.0±0.1 1.0±0.1 1.0±0.1 0.65 
SBP, mm Hg 133.8±17.2 135.4±17.4 131.7±16.7 0.20 
DBP, mm Hg 72.2±9.6 74.0±9.7 70.0±9.0 0.01 
Walking Performance Tests     
6 MWT distance, m 366.6±61.9 353.3±65.0 383.8±53.6 0.003 
Gait Speed, m/sec 0.8±0.2 0.8±0.2 0.9±0.2 0.0002 
Prevalent Health Conditions     
Hypertension 65(45.8) 44(55.0) 21(33.9) 0.01 
Diabetes Mellitus 20(14.1) 11(13.8) 9(14.5) 0.90 
Arthritis 33(23.4) 21(26.3) 12(19.7) 0.36 
Chronic Pulmonary Disease 16(11.3) 10(12.5) 6(9.7) 0.79 
Modified Modified Balke Protocol 35(24.7) 25(31.3) 10(16.1) 0.04 
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Table 4.6 Association Between 6 MWT Distance and Functional Exercise Capacity 
 Logistic Models 
Characteristics Unadjusted Age and Sex 
Adjusted 
Fully Adjusted 

















Height, per 1 cm   
1.02 
(0.96,1.09) 
Waist circumference, per 1 cm   
1.00 
(0.96,1.04) 
SBP, per 5 mm Hg   
1.09 
(0.94,1.26) 
DBP, per 5 mm Hg   
0.67 
(0.51,0.88) 
Hypertension   
0.36 
(0.15,0.88) 
Diabetes Mellitus   
1.01 
(0.30,3.32) 
Pulmonary Disease   
0.80 
(0.21,3.05) 
Arthritis   
0.71 
(0.28,1.81) 
Modified Treadmill Protocol   
0.33 
(0.12,0.89) 
Abbreviations: 6 MWT represents 6 Minute Walk Test; cm, centimeter; y, year; SBP, 
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Table 4.7 Association between 6 MWT Performance and Functional Exercise Capacity 
6 MWT 







 (%) LR + LR - 
240.79 - 314.56 100 0 43.66 1.00  
320.04 - 348.39 90.32 28.75 55.63 1.27 0.34 
 352.05 - 381.31 77.42 53.75 64.08 1.67 0.42 
382.22 - 414.53 53.23 71.25 63.38 1.85 0.66 
416.67 - 560.23 24.19 83.75 57.75 1.49 0.91 
>560.23 0 100 56.34  1.00 
Abbreviations: 6 MWT distance refers to Six Minute Walk Test; m, meters; %, percent; LR +, 
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5.0  DISCUSSION 
5.1 SUMMARY OF FINDINGS 
This dissertation evaluated the utility of cardiorespiratory fitness in community-dwelling older 
adults as it relates to subclinical cardiovascular disease and the prediction of health outcomes.  
Additionally, this dissertation evaluated the relationship between cardiorespiratory fitness as 
measured by a walk-based test and the conventional treadmill-based exercise test.  All three 
studies measured cardiorespiratory fitness and were based on community-based older adult 
participants of the Cardiovascular Health Study. Chapter 2 measured cardiorespiratory fitness 
using a time-based walking test, the 6 Minute Walk Test.  Chapters 3 and 4 included an 
assessment of cardiorespiratory fitness with the conventional treadmill-based exercise test.   
As shown in Chapter 2, in this cohort of community-dwelling older adults, the 
performance distance on a 6 Minute Walk Test was an independent predictor of all-cause 
mortality.  This study suggests the 6 Minute Walk Test is a useful measure of functional exercise 
capacity with prognostic significance which adds to the previous literature in disease-specific 
patient populations and extends its prognostic significance to community-dwelling older adults 
with a wide range of health and functional capacity. 
The relationships between two noninvasive measures of coronary artery disease, the 
treadmill-based exercise test and coronary artery calcification, in a cohort of community-
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dwelling older adults without prevalent cardiovascular disease are displayed in Chapter 3.  In this 
cohort, the duration of exercise on treadmill testing, a  measure of cardiorespiratory fitness, was 
not significantly associated with the extent of coronary artery calcification.  The results did 
reveal that the discriminatory ability of coronary artery calcification in the detection of flow-
limiting coronary disease may persist in oldest old aged adults. 
In the final chapter (Chapter 4), the 6 Minute Walk Test performance was shown to be a 
useful tool in the identification of treadmill test capable community-dwelling older adults 
without prevalent cardiovascular disease.  Additionally, the 6 Minute Walk Test performance 
was useful in the determination of functional exercise capacity as  measured by the conventional 
exercise treadmill test. 
5.2 PUBLIC HEALTH SIGNIFICANCE 
Given the age-related increase in the prevalence of cardiovascular diseases and other chronic 
health conditions, the aging of U.S. population calls for simple, safe, and low cost tools for 
screening and prevention of disease.  Although the conventional method of using treadmill or 
cycle ergometry exercise testing can provide a precise assessment of fitness, walk-based testing, 
such as that with the 6 MWT, can serve as a more practical tool in older adults.   
Taken together, our findings based on the CHS cohort provide support for the clinical 
application of the 6 MWT for screening purposes of community-dwelling older adults.  First, the 
association of CAC and treadmill exercise induced ischemia may reflect the continued 
discriminatory ability of CAC in older adults.  Secondly, the 6 MWT performance, as a 
reflection of cardiorespiratory fitness, can serve as a tool in the prediction of mortality.  Since 
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fitness is a marker of physical activity, the performance on the 6 MWT can assist practitioners in 
public health interventions aimed at promoting physical activity.  Lastly, the 6 MWT 
performance in older adults can provide clinicians with a quick measure discriminating the 
treadmill capable individuals, potentially reducing healthcare resource utilization in terms of 
unsuccessful treadmill test referrals.  Additionally, the 6 MWT performance can serve clinicians 
as a quick measure of functional capacity in older adults, which may aid clinicians in utilization 
of both appropriate healthcare and community-based resources. 
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